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There is a growing literature of clinical studies of bone marrow (BM) cell therapy for 
liver cirrhosis. At present, the optimum choice of cell type(s) and the mechanism(s) 
of effect remain undefined. Cells of the monocyte-macrophage lineage have key roles 
in the development and resolution of liver fibrosis. Therefore, I tested the therapeutic 
effects of these cells in the context of experimental murine liver fibrosis. 
 
The effects of unmanipulated, syngeneic macrophages, their specific BM precursors 
and unfractionated (whole) BM cells were examined in the iterative carbon 
tetrachloride model of liver fibrosis. BM-derived macrophage (BMM) delivery 
resulted in early chemokine upregulation with the hepatic recruitment of 
endogenous macrophages and neutrophils. These cells delivered matrix 
metalloproteinases-13 and -9 respectively, into the hepatic scar. The effector cell 
infiltrate was accompanied by increased levels of the anti-inflammatory cytokine IL-
10. A reduction in hepatic myofibroblasts was followed by reduced fibrosis detected 
4 weeks after macrophage infusion. Serum albumin levels were elevated at this time. 
Upregulation of the liver progenitor cell mitogen TWEAK preceded expansion of the 
progenitor cell compartment. BMM delivery increased hepatic expression of 
cytokines with reparative effects (including colony stimulating factor-1, insulin-like 
growth factor-1 and vascular endothelial growth factor). In contrast to the effects of 
differentiated macrophages, liver fibrosis was not significantly improved by the 
application of macrophage precursors and was exacerbated by whole BM. BMMs did 
not affect liver fibrosis or regeneration in the 1% DDC model of biliary disease.  
 
These effects were only detected following the intraportal delivery of BM cells. The 
peripheral (tail) vein administration of BMMs, either singly or repeatedly did not 
recapitulate the therapeutic phenotype. This was investigated by in vivo tracking of 
BMMs constitutively expressing green fluorescent protein (GFP). The peripheral 
administration route resulted in the early (1 hour) accumulation of BMMs within the 
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pulmonary system. This was followed by delayed hepatic engraftment, which was 
also numerically reduced (<30%) compared with intraportal administration.  
 
Macrophage cell therapy improves clinically relevant parameters in experimental 
chronic liver injury. Paracrine signalling to endogenous cells amplifies the effect. The 





Chronic liver disease is a major global cause of ill health and death. Unfortunately, 
effective and safe treatment is not available for many of these patients. Experimental 
reports have suggested that injecting patients with cells derived from the bone 
marrow (BM) could improve the most advanced stage of chronic liver disease 
(termed cirrhosis). Clinical studies have already begun, however, there is limited 
understanding of the best type(s) of BM derived cell to use and how these cells may 
help in cirrhosis. Studies in animal models provide an opportunity to determine 
these factors. 
 
Macrophages are a type of white blood cell (leucocyte) that originates from the BM. 
These cells have previously been shown to have important roles in liver scarring and 
healing. The effects of macrophages and also their BM parent cells were tested in the 
carbon tetrachloride (CCl4) model of mouse chronic liver disease. CCl4 causes injury 
to the bulk of the liver’s cells and has similarities with the most common human 
chronic liver diseases. 
 
The direct injection of donor macrophages into the portal vein that leads directly into 
the liver was soon followed by the homing of many more of the recipient’s own 
leucocytes from their blood system into the injured liver. Increased amounts of liver 
proteins that reduce inflammation and promote healing were also detected. The 
recipient leucocytes that had been recruited into the liver made significant amounts 
of key scar degrading enzymes. There followed a reduction in liver scarring with 
improved regeneration. Macrophages, but not their BM parent cells, caused these 
effects. 
 
Interestingly, injecting macrophages into a peripheral vein that is easily accessed 
through the skin rather than a deep vein that leads directly to the liver did not lead to 
the same improvements in liver scarring and regeneration. The peripheral injection 
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of macrophages resulted in many getting trapped in the lung circulation before 
arriving at the liver with significantly fewer lodged in the liver in the first 24 hours.  
These findings suggest that macrophage cell therapy may have potential as a 
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In the United Kingdom, liver disease is currently the fifth most common cause of 
death. There was a 25% increase in deaths due to liver disease between 2001 and 
2009. In contrast, the incidences for the top four causes of mortality are not rising. 
Over 90% of people who die from liver disease are under 70 years of age. 
(http://www.statistics.gov.uk/) This therefore represents a significant and growing 
burden on society in terms of health, productivity and resource demand. Cirrhosis is 
the most prevalent form of severe liver disease. End stage liver disease with its 
accompanying complications of liver failure, portal hypertension and hepatocellular 
carcinoma is the most frequent indication for liver transplantation. There are 
insufficient donor livers available to cope with the demand. Furthermore, liver 
transplantation with its attendant mortality and morbidity including the requirement 
for lifelong immunosuppression is not appropriate for many cirrhotic patients. There 
is therefore, an urgent need for novel therapies to reduce both the morbidity and 
mortality from cirrhosis. 
 
Liver fibrosis and ultimately cirrhosis is almost invariably the final common pathway 
of chronic hepatic injury. Worldwide, chronic viral hepatitis, alcohol excess and non-
alcoholic steatohepatitis associated with the metabolic syndrome account for the 
majority of chronic liver disease. In addition, autoimmune and inherited metabolic 
aetiologies also contribute to the development of cirrhosis. Specific management of 
the cause (e.g. antiviral therapy, cessation of alcohol) can limit further tissue damage. 
The natural history of cirrhosis is relatively slow, usually being measured in years. 
Given the considerable physiological reserve of the liver, the disease process is 
typically clinically silent until the advanced stages. Therefore, despite improvements 
in public health and the screening and treatment of liver diseases, presentation with 
late stage disease is common. The asymptomatic phase of cirrhosis is considered 
“compensated”. Ongoing damage can eventually result in the clinical manifestations 
of portal hypertension and liver dysfunction. This “decompensated” phase is 
characterised by the development of ascites, gastrointestinal bleeding, jaundice and 
encephalopathy in addition to an increased risk of developing liver cancer. 
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Longitudinal data indicate that this progression from compensated to 
decompensated disease is associated with a significant increase in mortality 
(D'Amico, Garcia-Tsao et al. 2006). Scoring systems such as the Child-Pugh (C-P) 
score and model for end-stage liver disease (MELD) are used in routine clinical 
practice and correlate with increasing disease severity and worse outcomes. When 
assessing the potential utility of novel therapies for cirrhosis, it is important to 
consider the intrinsically linked processes of liver fibrosis and regeneration in this 
clinical context. 
 
Liver fibrosis  
In the healthy uninjured liver, the production of extracellular matrix (ECM) is 
balanced by its degradation. Chronic inflammation virtually regardless of aetiology, 
disrupts this homeostasis effectively resulting in an aberrant wound healing 
response (Iredale 2007). Damage to hepatocytes and non-parenchymal liver cells (e.g. 
cholangiocytes and endothelial cells) causes the release of inflammatory factors 
which interact with a number of cell types including hepatic stellate cells, 
macrophages and fibroblasts to promote extracellular matrix (ECM) deposition. It is 
now clear that liver fibrosis is a bi-directional process. Significant resolution of 
fibrosis is possible in both humans and experimental models. Hepatic stellate cells 
and macrophages are important mediators of fibrosis regression and therefore 
represent potential targets for anti-fibrotic therapies.  
 
Extracellular matrix during fibrogenesis 
The predominant components of ECM in the normal liver are collagens type I, III, IV, 
V and VI and glycoproteins such as fibronectin and laminin (Iredale, Thompson et al. 
2013). With chronic injury, this is progressively replaced by fibrillar collagen 
(particularly type I), laminin, proteoglycans and ultimately elastin (Friedman 1993; 
Pellicoro, Aucott et al. 2012).  Histologically, there is capillarisation of the hepatic 
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sinusoids which has direct effects on hepatocyte function. Subsequently, fibrosis 
develops within the parenchyma itself. The anatomical distribution may reflect the 
initial pattern of inflammation e.g. pericentral inflammation and then fibrosis in 
alcoholic liver disease in contrast to the periportal distribution in chronic viral 
hepatitis and chronic cholestatic disease (Friedman 1993). With continued injury, 
vascular structures become linked by scar tissue. Eventually this architectural 
disruption contributes to the clinical manifestation of portal hypertension. The 
chronically compromised hepatocytes and non-parenchymal cells situated in the 
fibrotic liver are unable to execute fully their physiological roles resulting in the 
clinical features of liver failure. Though incompletely understood, insights into the 
propensity for tumorigenesis in the cirrhotic liver highlight the biochemical and 
mechanical effects of fibrosis in conjunction with inflammatory and regenerative 
mediators promoting genome instability (Zhang and Friedman 2012). 
 
Cellular mediators of fibrosis 
Hepatic myofibroblasts are the major source of ECM in injury (Gabele, Brenner et al. 
2003). Myofibroblasts may derive from a number of cell populations including 
fibrocytes (Kisseleva, Uchinami et al. 2006), portal myofibroblasts (Kinnman and 
Housset 2002) and mesenchymal stem cells (MSCs) (Russo, Alison et al. 2006). 
However, the main functional source is considered to be via transdifferentiation of 
hepatic stellate cells (Maher and McGuire 1990; Wells, Kruglov et al. 2004). In the 
normal liver, quiescent hepatic stellate cells reside in the sub-endothelial Space of 
Disse. These mesenchymal cells are rich in retinoid and lipid. Injurious stimuli 
converge on the stellate cell triggering a switch to a myofibroblastic phenotype. This 
process is modelled by culturing hepatic stellate cells on tissue culture plastic which 
has allowed a detailed understanding of the signalling processes involved in this 
activation (Friedman, Rockey et al. 1992). The myofibroblastic phenotype is 
characterised by the synthesis of α-smooth muscle actin (α-SMA) and collagen. There 
is accompanying expression of factors that regulate ECM turnover (such as matrix 
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metalloproteinases (MMPs) and their tissue inhibitors (TIMPs)) as well as vascular 
reactivity (Friedman, Roll et al. 1985; Rockey 2001). Inflammatory cytokines such as 
TGF-β (Gressner, Weiskirchen et al. 2002) and PDGF (Pinzani, Gesualdo et al. 1989) 
promote collagen I expression and proliferation (respectively) of stellate cells. Thus 
inflammation is critical for the initiation and propagation of scar deposition (Iredale 
2007). 
 
Liver macrophages, also known as “Kupffer cells”, are largely replenished by 
monocytes derived from the BM (Klein, Cornejo et al. 2007). Cells from the 
monocyte-macrophage lineage have key roles in fibrogenesis. Duffield and 
colleagues used the transgenic diphtheria toxin receptor (DTR) model to achieve the 
selective ablation of mouse macrophages. The depletion of macrophages during liver 
injury resulted in less fibrosis indicating that macrophages are important for the 
generation of liver fibrosis during this inflammatory phase (Duffield, Forbes et al. 
2005). Subsequent work by Karlmark and colleagues identified the inflammatory Ly-
6Chi monocyte subset as having pro-fibrotic effects, potentially mediated by hepatic 
stellate cell activation (Karlmark, Weiskirchen et al. 2009). 
 
 
Molecular mediators of fibrosis 
The MMP family of proteins are zinc-dependent proteolytic enzymes that are 
conventionally categorised according to their main substrate. The degradation of 
fibrillar collagen by collagenases (such as MMP-13 and MMP-8) results in gelatin 
products which in turn are cleaved by gelatinases A (MMP-2) and B (MMP-9). The 
gelatinases are relatively promiscuous in terms of their substrate specificity; in 
addition to their action on gelatins, there is also collagenase (MMP-2) and elastase 
(MMPs-2 and -9) activity. Whilst MMPs are responsible for the degradation of ECM 
constituents, they also play a role in fibrogenesis by contributing to ECM 
remodelling thereby facilitating scar deposition. MMP-12 (macrophage 
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metalloelastase) mediates elastin degradation which has been shown to occur even 
during long term fibrogenesis (Pellicoro, Aucott et al. 2012). Hepatic stellate cells 
secrete MMP-13 resulting in the local destruction of surrounding ECM with 
liberation of pro-fibrogenic cytokines such as TGF-β.(Yang, Zeisberg et al. 2003)  
MMP-2 is expressed by hepatic stellate cells and is an autocrine proliferation and 
migration factor (Benyon, Hovell et al. 1999). The tissue inhibitors of MMP (TIMPs)   
are a family of proteins which bind MMPs. Formation of these complexes therefore 
renders the MMPs physically unavailable to contribute to ECM degradation. 
Upregulation of myofibroblast derived TIMP-1 disturbs this balance during liver 
fibrogenesis resulting in net scar deposition (Iredale 1997). 
 
Liver fibrolysis 
Liver fibrosis has a reversible component that may become apparent when the 
injurious stimulus is removed. This is now a well-recognised clinical phenomenon; 
for example, abstinence in patients with cirrhosis due to alcohol can result in 
considerable hepatic recompensation and successful antiviral therapy for patients 
with hepatitis B or C is associated with significant regression of fibrosis (Poynard, 
McHutchison et al. 2002; Dienstag, Goldin et al. 2003). The mechanisms underlying 
these effects have been examined in rodent models.  
 
The recovery phase from fibrosis that occurs after injury is accompanied by 
myofibroblast apoptosis and a decrease in collagen production (Iredale, Benyon et al. 
1998). The reduced amount of scar tissue is associated with improvement in the 
regenerative capacity of the liver (Issa, Zhou et al. 2003; Kallis, Robson et al. 2011). 
Due to the often asymptomatic nature of liver fibrosis and compensated cirrhosis, 
patients frequently present with advanced disease. For many such patients, the 
medical treatments for the various causes of chronic liver disease are either non-
existent, not available or inadequate to permit sufficient recovery and prevent 
eventual liver failure. Therefore targeting these basic processes of fibrogenesis and 
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fibrolysis represents a rational therapeutic avenue for disease modification in 
cirrhosis. 
Cellular and molecular mediators of fibrolysis  
Following the cessation of liver injury, macrophages readily engraft the hepatic scar. 
This has been examined using the CD11b-DTR mouse model (Duffield, Forbes et al. 
2005). In this experimental scenario, depletion of macrophages during the recovery 
phase after liver injury results in an attenuated reduction in liver fibrosis. This 
indicates that macrophages have a critical role in the remodelling process. The bone 
marrow (BM) origin of almost half of these scar associated macrophages (SAMs) 
highlights the key role of BM cells in the regulation of fibrosis. The mechanisms 
underpinning this anti-fibrotic role for macrophages during the recovery phase were 
subsequently examined (Fallowfield, Mizuno et al. 2007). After cessation of injury, 
increased numbers of macrophages were detected within the scar with concurrently 
elevated levels of hepatic MMP-13 expression. Further experiments showed that scar 
associated macrophages (SAMs) were the primary source of this collagenase. DTR 
mediated macrophage deletion during recovery in CD11b-DTR mice resulted in a 
marked reduction of MMP-13 positive cells and whole tissue levels of MMP-13 
transcript. Furthermore, fibrosis resolution was partially abrogated in transgenic 
MMP-13 knockout mice relative to wild type. Taken together, these data support a 
role for macrophage produced MMP-13 as a critical mediator of scar remodelling 
during recovery. Other macrophage (and non-macrophage) derived MMPs would 
also be expected to have important roles in fibrosis regression, as indicated by the 
only partial reduction in fibrolysis in the MMP-13 knockout mice. 
 
In addition to the transient upregulation of MMP-13 soon after the cessation of liver 
injury, there is also a prolonged increase in MMP-9 expression during the resolution 
process. Macrophages have been considered the predominant source of MMP-9 in 
the liver (Knittel, Mehde et al. 1999), however during the recovery phase, MMP-9 
expressing neutrophils as well as macrophages have been identified (Higashiyama, 
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Inagaki et al. 2007). The functional importance of MMP-9 has been demonstrated by 
adenovirally transferred MMP-9 promoting myofibroblast apoptosis and reducing 
fibrosis despite ongoing injury.(Roderfeld, Weiskirchen et al. 2006) Mechanistically, 
part of this action of MMP-9 on myofibroblasts may be mediated by the cleavage of 
ECM ligands which otherwise provide survival signals through alpha(v)beta(3) 
integrin (Zhou, Murphy et al. 2004). This conceptually ties in the hepatic influx of 
circulating, MMP expressing cells associated with the cessation of injury to the 
observed ECM degradation and reduction in fibrogenic myofibroblasts. 
 
The role of neutrophils has been examined in fibrosis regression following the release 
of extra-hepatic bile duct ligation (BDL). The recovery phase is characterised by the 
influx of neutrophils to the liver and increased levels of MMP-8 (neutrophil 
collagenase) (Harty, Huddleston et al. 2005). Given its activity against collagen I, 
MMP-8 represents an attractive therapeutic target. Hepatic over-expression of MMP-
8 following gene therapy via an adenoviral vector causes significant improvement in 
fibrosis in both hepatitic (carbon tetrachloride, CCl4) and cholestatic (BDL) injury 
models (Siller-Lopez, Sandoval et al. 2004). Macrophage depletion during the 
recovery period after the release of BDL decreases the chemoattractant signals for 
neutrophil migration with impairment of fibrolysis (Harty, Papa et al. 2008). The 
direct deletion of neutrophils also impairs collagenase activity and scar resorption 
(Harty, Muratore et al. 2010). These data suggest a specific anti-fibrotic role for 
neutrophils during recovery in this model of sterile liver inflammation and fibrosis. 
 
Bone marrow cells contribute to liver fibrosis and fibrolysis 
The analysis of tissue from patients receiving sex mismatched liver transplantation 
yielded new insights into the BM origin of non-parenchymal liver cells. By using 
identification of the Y chromosome as a marker of cellular origin, it was shown that 
the BM supplies a significant proportion of myofibroblasts in liver disease (Forbes, 
Russo et al. 2004). By testing cell populations that were enriched for either 
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haematopoietic stem cells (HSCs) or mesenchymal stem cells (MSCs) in murine 
models of liver fibrosis, it became apparent that the BM MSCs were most likely to 
differentiate into collagen producing myofibroblasts within the injured liver (Russo, 
Alison et al. 2006). This was confirmed in subsequent work transplanting human 
MSCs into immunodeficient mice which were then treated with CCl4 to induce 
hepatic fibrosis (di Bonzo, Ferrero et al. 2008). Whilst the MSCs could infrequently 
adopt a “hepatocyte-like” phenotype, these cells were far more likely to develop a 
myofibroblastic phenotype and thus have the potential to contribute to fibrogenesis 
within the injured liver. This has important implications for cell therapy in liver 
cirrhosis; BM stem cells or their progeny that are of mesenchymal lineage could have 
deleterious effects by supporting fibrogenic cell populations. 
 
Transplanting enhanced green fluorescent protein (EGFP) expressing BM cells into 
wild type recipients prior to inducing fibrosis with CCl4 injections allows the tracking 
of BM cells (Higashiyama, Inagaki et al. 2007). As per Duffield et al (Duffield, Forbes 
et al. 2005), approximately half of the liver macrophages had a directly traceable BM 
origin. Early in the recovery phase after liver injury, there are BM derived MMP-13 
expressing macrophages and MMP-9 expressing neutrophils within the scar. 
Interestingly, applying exogenous granulocyte-colony stimulating factor (G-CSF) 
prior to recovery enhanced the migration of BM cells into the liver and also 
significantly accelerated fibrolysis after injury (Higashiyama, Inagaki et al. 2007). 
This suggests that BM cells and their recruitment into the injured liver are feasible 
therapeutic targets for fibrosis regression. 
 
Liver regeneration 
In addition to the range of viral, immune and metabolic insults that can affect the 
liver, the ongoing requirement to process nutrients and toxins from the environment 
poses a continuous challenge to the regenerative capacity of the liver. The essential 
synthetic, metabolic, detoxification and immune functions of the liver must be 
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executed by a sufficient parenchymal mass in order to maintain the physiological 
state. Therefore even in health, there is a substantial regenerative burden on the liver. 
This demand is even greater in the context of chronic liver disease, wherein the 
regenerative response involves additional complexity. 
 
The primary source of hepatocytes in the healthy (uninjured) liver is mature 
epithelia. Experimental two thirds partial hepatectomy in this context is followed by 
full restoration of liver mass by mitotic cell divisions within 10 days. In humans, an 
analogous situation may occur following tumour resection or living donor 
transplantation. This efficient mode of regeneration is controlled by a number of 
cytokines e.g. tumour necrosis factor (TNF) and interleukin (IL)-6 and growth factors 
e.g. hepatocyte growth factor (HGF) (Fausto, Campbell et al. 2006). 
 
When there is chronic damage to hepatocytes with associated senescence (Marshall, 
Rushbrook et al. 2005), then this method may not be able to generate sufficient 
numbers of hepatocytes. In this context, the liver’s facultative stem cell compartment 
is activated. These cells are termed liver progenitor cells (LPCs) or oval cells. LPCs 
originate from the distal branches of the biliary tree (the Canals of Hering) and are 
bipotential, differentiating into either biliary epithelia or hepatocytes. Inflammation 
is considered a key stimulus for LPC proliferation (Knight, Matthews et al. 2005). A 
number of cytokines have been shown to cause LPC activation including IL-6, 
interferon γ and members of the TNF superfamily such as TNFα, lymphotoxin and 
TNF-like weak inducer of apoptosis (TWEAK) (Bird, Lorenzini et al. 2008). TWEAK 
is of particular interest as it has been identified as a selective mitogen for LPCs 
(Jakubowski, Ambrose et al. 2005). Its cognate receptor fibroblast growth factor-
inducible 14 (Fn14) is a marker of LPCs and is upregulated during the course of LPC 
activation (Tirnitz-Parker, Viebahn et al. 2010). The process of stem cell expansion 
and then differentiation into the final lineage is essentially continuous, therefore the 
selection of stem cell markers is a challenging area. Cytokeratin-19 (CK-19), EpCam 
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and Fn-14 are amongst the best validated and recognised in the literature (Yovchev, 
Grozdanov et al. 2008). 
 
Bone marrow and liver regeneration 
LPCs possess some of the markers usually seen on BM stem cells such as THY1, and 
CD34. This resulted in speculation that these cells could derive from the BM. Early 
reports suggested that the progeny of BM derived stem cells could make a significant 
contribution to the hepatocyte mass. (Petersen, Bowen et al. 1999; Alison, Poulsom et 
al. 2000; Theise, Badve et al. 2000; Theise, Nimmakayalu et al. 2000) BM derived 
(haematopoietic) stem cells are routinely isolated, stored and transplanted in clinical 
practice. Therefore these findings triggered a large amount of research into this area 
in the hope that it could yield new therapeutic options which used existing clinical 
frameworks. Whilst some data support the possibility that BM could differentiate 
into epithelia, the physiological significance of such a route is likely to be extremely 
limited, if present at all. Using a variety of cell tracking techniques, many groups 
have examined the contribution of the BM stem cells to liver regeneration in both 
experimental models and human tissue from patients that have undergone organ 
transplantation. These studies have largely found the contribution of BM stem cells 
to parenchymal regeneration to be minor (Thorgeirsson and Grisham 2006; Vig, 
Russo et al. 2006). 
 
Substantial, functional parenchymal replacement by BM derived cells has been 
reported in one particular experimental setting: the FAH deficient mouse (Lagasse, 
Connors et al. 2000). Subsequent studies definitively proved that this finding was in 
fact the result of cell fusion between BM derived macrophages and hepatocytes 
(Wang, Willenbring et al. 2003; Willenbring, Bailey et al. 2004). Whilst this was 
effectively a successful demonstration of “cellular gene therapy” the donor BM cells 
did not differentiate into hepatocytes but instead fused with host cells thereby 
rescuing an otherwise fatal metabolic error. In human clinical studies of cirrhosis it is 
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unlikely that these fusion cells would have such a strong selection advantage. 
Though the replacement of damaged hepatocytes with unmodified BM cells is no 
longer a realistic therapeutic aim, such work has revealed important new insights 
into the relationship between the liver and BM derived cells. 
Though LPCs are not of BM origin they have an intimate spatial association with 
cells that can originate from the BM such as hepatic stellate cells and macrophages 
(Lorenzini, Bird et al. 2010). Macrophage depletion has been shown to prevent the 
activation of LPCs during injury (Olynyk, Yeoh et al. 1998). This may relate to the 
functional importance of the macrophage mediated delivery of LPC mitogens to the 
stem cell niche.  Macrophages are the dominant source of TWEAK from infiltrating 
leucocytes in regenerating liver. Furthermore, the exogenous application of 
recombinant TWEAK causes LPC proliferation in vivo (Tirnitz-Parker, Viebahn et al. 
2010). 
 
Figure 1.1 summarises these concurrent processes of liver fibrosis and regeneration 
during chronic injury. Given the roles of macrophages in both liver fibrosis and 
regeneration, cells from the monocyte-macrophage lineage represent attractive 














Figure 1.1 Key processes in liver fibrosis and regeneration during 





Figure 1.1 Key processes in liver fibrosis and regeneration during 
chronic liver injury 
This figure illustrates the concurrent responses to chronic liver injury. There is 
expansion of scar producing hepatic myofibroblasts whilst liver macrophages have 
diverse roles in regulating both scar deposition and resorption. Simultaneously, 
ongoing tissue injury causes hepatocyte damage and proliferation and also activation 
of the progenitor cell compartment of the liver. This allows a degree of recovery of 
liver cell mass and function.  
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Cell therapy for liver cirrhosis  
As described, advancing liver injury places increasing demands on the functional 
compartments of liver regeneration. Failure to keep pace results in the clinical 
manifestations of organ failure, such as jaundice and encephalopathy. As liver 
fibrosis progresses, the capacity for hepatocyte mediated regeneration diminishes 
whilst structural changes in the liver contribute to portal hypertension and in turn 
ascites and variceal bleeding. The characteristic abnormal fibrotic architecture with a 
reduced number of compromised hepatic cells is not an environment conducive to 
naïve hepatocyte/hepatocyte-like cell engraftment and function. Studies attempting 
to provide parenchymal support in this manner have been generally unsuccessful 
and do not address all the clinical problems of cirrhosis. 
 
The structural and functional improvements observed after correction of specific 
aetiologies e.g. hepatitis B and C virus infection, autoimmune disease, chronic 
alcohol excess, offer hope to the prospect of clinically successful disease modifying 
therapy. Disease regression in turn may reduce the predisposition to liver cancer 
(Hosaka, Suzuki et al. 2013). Therefore the current rationale behind BM cell based 
therapies is to affect the underlying pathophysiological processes in order to 





Human studies of cell therapy for cirrhosis 
The incorrect suggestion that BM cells might significantly and directly supply 
hepatic parenchyma allied to the existing use of BM stem cells in clinical 
haematological practice was followed by a wave of studies of BM cell therapy for 
cirrhosis. These can be categorised in terms of the intended therapeutic cell type. 
 
Haematopoietic stem cells (HSCs) are pluripotent stem cells that comprise a very 
small fraction of the whole BM. These cells are capable of giving rise to all the major 
blood cell lineages. BM cell fractions can be enriched for HSCs through sorting using 
cell surface markers such as CD34 and CD133. The subset of CD34 positive cells that 
also express CD133 is considered to be further enriched for stem cells (de Wynter, 
Buck et al. 1998). In addition, CD34-/CD133 positive cells have been identified as 
having the capacity to form endothelial progenitor cells (Friedrich, Walenta et al. 
2006). Cell sorting increases both the cost and complexity of the process; a potential 
solution is the use of less purified cell fractions.  Mononuclear cells (MNCs) can be 
separated from BM relatively simply by density gradient centrifugation however, 
CD34 positive cells constitute only 1-2% of this population (Steen, Morkrid et al. 
1994)  and the proportion of true stem cells within this fraction is even smaller. 
Nonetheless, it is plausible that an “active” component of this therapy may reside in 
the non-stem cell fraction or even be the result of interactions between different 
donor cell types (Thomas 2009). 
 
Autologous candidate cells are initially harvested by either leukapheresis or direct 
BM aspiration. G-CSF is routinely given prior to leukapheresis in haematological 
practice to increase HSC yields from peripheral blood. Human studies in which 
HSCs are extracted from peripheral blood utilise this action of G-CSF in their 
protocols. The independent actions of G-CSF on the cirrhotic subject must therefore 
be considered. Animal data support roles for G-CSF in mobilising BM stem cells and 
also directly stimulating liver regeneration. During regeneration, there is hepatic 
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production of G-CSF whilst LPCs upregulate expression of the G-CSF receptor, 
proliferating in response to stimulation by this cytokine (Piscaglia, Shupe et al. 2007). 
 
Distinct from its use in cell therapy protocols, G-CSF itself has been studied as a 
treatment in cirrhosis. A G-CSF dose finding study in cirrhotics did not demonstrate 
a consistent improvement in liver function (Lorenzini, Isidori et al. 2008). A small 
randomised controlled trial of G-CSF therapy in patients with alcoholic 
steatohepatitis showed early increases in serum HGF, peripheral CD34 positive cell 
counts and LPC proliferation on paired biopsies taken 7 days apart, but did not show 
improvement in measures of liver function up to 28 days after treatment (Spahr, 
Lambert et al. 2008). Subsequently, a randomised control trial of G-CSF treatment in 
acute on chronic liver failure has shown promising results in this group of very sick 
patients. In addition to improving blood tests of liver and renal function, clinical 
indicators such as infection rate and encephalopathy improved. Most strikingly, the 2 
month mortality rate was more than halved by G-CSF therapy (17/24 control versus 
7/23 with G-CSF). As expected, G-CSF caused an increase in the number of 
circulating CD34 positive cells; this does not prove direct involvement in the 
mechanism of effect. The number of patients in this study was small and there was 
heterogeneity of both cirrhosis aetiology and cause of the acute deterioration. These 
factors limit the certainty and generalisability of the results. More recently, G-CSF 
was administered to patients with chronic hepatitis B virus (HBV) infection 
experiencing an acute deterioration in liver function. In line with the previous report, 
3 month mortality was more than halved by G-CSF (13/27 control versus 6/28 with G-
CSF) (Duan, Liu et al. 2013). These encouraging findings warrant further 
investigation and importantly the use of “G-CSF alone” control arms in cell therapy 
studies.  
 
Mesenchymal stem cells (MSCs) are a heterogeneous population of plastic adherent 
BM stromal cells characterised by their multi-potentiality (including down 
osteocytic, chondrocytic and adipocytic lineages) and the presence (and absence) of 
36 
 
specific surface markers (Kolf, Cho et al. 2007). This multipotentiality and their 
relative ease of accessibility in addition to their immunomodulatory properties 
(Ryan, Barry et al. 2007) has made MSCs an attractive candidate for cell therapy. As 
described, the long term stability and potential to differentiate into scar producing 
myofibroblasts (Russo, Alison et al. 2006; di Bonzo, Ferrero et al. 2008) are important 
caveats when considering the clinical use of MSC based therapy for cirrhosis 
(Thomas 2013). 
 
Haematopoietic stem cells 
A phase 1 study of autologous CD34 positive cells given to 5 cirrhotic patients was 
conducted by Gordon and colleagues (Gordon, Levicar et al. 2006). The aetiologies of 
cirrhosis were alcohol excess, primary sclerosing cholangitis (PSC) and chronic HBV 
or hepatitis C virus (HCV) infection. CD34 positive cells were mobilised by G-CSF 
administration and then isolated from the mononuclear cell fraction by magnet based 
cell sorting. The donor cells were manipulated by adherence to plastic and cultured 
in media containing a number of cytokines, including stem cell factor, GM-CSF, IL-3, 
and G-CSF. Between 1 x 106 and 2 x 108 cells were re-infused via the hepatic artery 
(n=2) or portal vein (n=3). There were no discernible changes in liver biochemistry or 
clinical parameters either over the initial 2 month period or on longer term follow up 
of 12-18 months. However, the primary endpoints of safety and acceptability were 
achieved (Levicar, Pai et al. 2008). The same group also published a report of 9 
patients with cirrhosis due to alcohol excess who had been abstinent for a minimum 
of 6 months (Pai, Zacharoulis et al. 2008). CD34 positive cells were isolated following 
G-CSF administration and cultured in similar conditions to their previous study. A 
mean dose of 2.3 x108 cells was injected into the hepatic artery without any detected 
short or long term complications. Liver chemistry and Child-Pugh score seemed to 
increase from baseline over the 3 month follow up period though the absence of a 




A multi-disciplinary group of radiologists and surgeons from Dusseldorf, Germany 
delivered CD133 positive BM cells into the hepatic portal vein (HPV) in non-cirrhotic 
patients undergoing hepatic resection (Furst, Schulte am Esch et al. 2007). 13 patients 
underwent pre-operative portal vein embolization as a regenerative stimulus 
followed by extended right hepatectomy for large hepatic malignancy (primary or 
secondary). The cell therapy group (n=6) additionally received between 2.4 and 12.3 
x106 autologous CD133 positive cells that had been positively sorted from BM 
aspirate. Cell recipients had significantly greater increases in radiologically 
determined liver volume, which allowed earlier tumour resection. One of the treated 
patients had liver fibrosis due to HCV infection however the majority of these 
patients did not have chronic liver disease. Nonetheless, it is biologically plausible 
that such a pro-regenerative effect might also be imparted to the cirrhotic patient. 
 
In a study from the Royan Institute in Iran, 4 patients with decompensated cirrhosis 
were given between 2.5 and 8 x106 BM derived CD34 positive cells. These were 
injected into the hepatic artery (HA) by a radiologically guided procedure 
(Mohamadnejad, Namiri et al. 2007). 1 of these patients (with autoimmune cirrhosis) 
experienced worsening renal failure and ultimately died of liver failure. The adverse 
event was attributed to contrast nephropathy in a cirrhotic patient with pre-existing 
renal dysfunction and caused the early termination of the study. This represents an 
important lesson for the research community in terms of the selection of subjects and 
the route of cell administration in this often frail group of patients. 
 
The effects of partially differentiated CD34 positive cells were studied in 48 cirrhotic 
patients recruited from hospitals in Cairo, Egypt (Salama, Zekri et al. 2010). 36 of 
these patients had chronic HCV infection whilst 12 had an autoimmune aetiology. 
Participants underwent G-CSF mobilisation prior to leukapheresis. CD34 positive 
cells were isolated, cultured and expanded for a further week in media containing 
GM-CSF and also growth factors derived from buffalo rat liver extract. The rationale 
behind the cell culturing process was to begin differentiation towards a hepatocyte 
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like phenotype. RT-PCR demonstrated that the cells expressed the genes for albumin 
and also α1-antitrypsin during the protocol. 1x109 cells were infused via the HPV, 
unless hepatofugal flow was detected in which case the HA was used. Serious 
adverse events were a single case of post-procedural haemoperitoneum which 
required blood transfusion and 2 gastrointestinal bleeds which occurred 1 week after 
cell delivery. One of these haemorrhages was endoscopically controlled however the 
other was fatal. From baseline, liver biochemistry improved in patients of both HCV 
and autoimmune aetiology however the lack of a control group limits the 
appreciation of any therapeutic effect.  
 
This group also conducted a randomised controlled trial of CD34/133 positive cells in 
patients with HCV cirrhosis.(Salama, Zekri et al.) 90 patients received 5 days of G-
CSF treatment prior to BM aspiration from which CD34/ CD133 positive cells were 
selected. 5x107 cells were re-infused via the HPV. Importantly, the 50 control subjects 
received control water injections instead of G-CSF. The G-CSF/cell recipients had 
improvements in liver biochemistry, Child-Pugh score and measures of clinical 
status which lasted to the end of the 6 month follow up period. Whether these 
positive effects are attributable to the cells, G-CSF or a combination is undefined. 
(Thomas 2013) 
 
Mesenchymal stem cells 
Reports of MSC delivery to cirrhotic patients have given mixed results. The first 
published study of MSC therapy in cirrhosis was from the University of Tehran, Iran 
(Mohamadnejad, Alimoghaddam et al. 2007). 4 patients with decompensated 
cirrhosis (3 deemed cryptogenic and 1 of autoimmune aetiology) on the liver 
transplant waiting list received between 1 and 6 x 107 MSCs via a peripheral vein.  
These cells were derived from BM and cultured in vitro. 12 months later, all 4 patients 
were subjectively better as determined by quality of life questionnaire scores whilst 3 




Another study from the Royan Institute used MSCs cultured from BM aspirate which 
then underwent a hepatocytic differentiation protocol. This process took 
approximately 2 months. Between 3 and 5 x 107 autologous cells were given to 8 
cirrhotic patients. The breakdown of their cirrhosis aetiologies was: HBV (n=4), HCV 
(n=1), cryptogenic (n=2) and chronic alcohol excess (n=1). The cells were injected into 
the HPV in 6 patients and into a peripheral vein in 2 patients in whom the intraportal 
route was not technically possible. All 8 cell recipients had improved MELD scores 6 
months after treatment (mean score from 17.9 to 10.7) in this uncontrolled study 
(Kharaziha, Hellstrom et al. 2009). 
 
The largest cell therapy trial to date was performed in the setting of liver failure due 
to HBV cirrhosis (Peng, Xie et al. 2011). Autologous MSCs were given to 52 patients 
who consented to cell therapy whilst 105 control subjects were matched for age, sex, 
liver biochemistry and MELD score. MSCs were derived from BM aspirate and 
delivered via the HA. 2 weeks after MSC delivery, serum albumin and bilirubin 
levels were improved. Within another week, prothrombin time (PT) and MELD 
scores had also significantly improved. These benefits were not sustained beyond 36 
weeks after cell infusion. No significant differences in hepatocellular carcinoma 
(HCC) rate or survival were detected. 
 
Umbilical cord derived MSCs have been used in a study of acute on chronic liver 
failure due to HBV infection (Shi, Zhang et al. 2012). 24 patients received cells via a 
peripheral vein on 3 occasions at 4 week intervals. 19 control subjects received saline 
infusions. Blood test results, MELD score and 12 week survival improved in MSC 




Mononuclear cells  
Terai and co-workers at Yamaguchi University Hospital in Japan recruited 9 cirrhotic 
patients for an uncontrolled study of MNC therapy. The aetiologies were HBV (n=3), 
HCV (n=5) and cryptogenic (n=1). Between 2.21 and 8.05 x109 BM derived unsorted 
mononuclear cells were injected via a peripheral vein. 2.39% of infused cells were 
CD45 positive / CD34 positive. Significant improvements from baseline in serum 
albumin and Child-Pugh score were found up to 6 months after infusion of the MNC 
fraction (Terai, Ishikawa et al. 2006). 3 of these patients also had pre- and 4 week 
post-therapy liver biopsies. These demonstrated an increase in immunohistochemical 
markers of regeneration (α-fetoprotein and proliferating cell nuclear antigen).  
 
Striking improvements were found in 2 abstinent patients with decompensated 
alcoholic cirrhosis who received 4 or 6.93 x106 CD34 positive cells per kg within the 
MNC fraction (Yannaki, Anagnostopoulos et al. 2006). These cells were obtained 
from leukapheresis product following G-CSF mobilisation and then re-infused via a 
peripheral venous route. The clinical and biochemical recovery was greatest 1 year 
after treatment. Without a control group it is not possible to determine benefit 
categorically. Furthermore, substantial improvement in liver remodelling and 
function is well recognised following abstinence from alcohol. This highlights the 
importance of robust, controlled trials to move the field forward. 
 
A randomised controlled trial of autologous MNCs in cirrhosis was undertaken at 
the Hospital Sao Rafael in Salvador, Brazil (Lyra, Soares et al. 2010). 30 patients with 
a variety of aetiologies (predominantly alcohol excess, HCV infection and 
cryptogenic) who were on the liver transplant waiting list were randomised. Half of 
the subjects received mononuclear BM cells (between 1.6 and 11.2 x108) via the HA. 
Though no serious adverse events were detected in the first 3 months, 3 patients in 
the MNC therapy arm died from complications of cirrhosis at 6, 8 and 10 months 
whilst 2 died in the control arm (with an additional patient undergoing liver 
transplantation due to progressive liver failure). Serum albumin levels increased 
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transiently following MNC infusion with a similarly short term trend of 
improvement in serum bilirubin. Improvements in Child-Pugh score (but not MELD) 
reached statistical significance in cell recipients over the first 3 months; the strength 
of this effect was not maintained to the 12 month time point. 
 
An uncontrolled series from Seoul, South Korea examined 10 patients with HBV 
cirrhosis who received with 1x108 BM derived MNCs via a peripheral vein (Kim, 
Park et al. 2010). The greatest improvements in serum albumin and prothrombin 
time were 6 months after cell infusion. Childs-Pugh score (but not MELD) also 
improved at 6 months along with subjective features of quality of life. Serial liver 
biopsies were taken before and 1, 3 and 6 months after therapy. These demonstrated 
a significant increase in LPC numbers with an accompanying trend towards 
increased numbers of proliferating hepatocytes 3 months after MNC infusion. This 
effect did not persist to the 6 month biopsy. 
 
BM derived MNCs were studied as a potential adjunct to the Kasai procedure in a 
group of paediatric patients with extra-hepatic biliary atresia. This controlled study 
from New Delhi, India tested the effects of 4 x107 MNC delivered via the HA and/or 
HPV during surgery. If these vessels were not accessible then superior mesenteric 
vein radicals or trans-hepatic routes were used (Sharma, Kumar et al. 2011). MNC 
recipients had improved serum bilirubin, alkaline phosphatase and transaminases 
within the first post-operative week. The reduction in serum bilirubin was 
maintained during the following year. MNC therapy conferred fewer episodes of 
cholangitis and improved survival rates during the year of follow up. 
 
I have collaborated with a group of researchers from Rio de Janeiro, Brazil on a Phase 
1 study of BM derived MNCs (Couto, Goldenberg et al. 2011). A novel feature of this 
study was tracking donor cells in vivo by labelling them with 99Tc-SnCl2. Whole body 
scintigraphy allowed determination of hepatic radiotracer retention following cell 
injection into the HA. This demonstrated 41% hepatic retention at 3 hours and 32% 
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by 24 hours after cell delivery. Improvements in serum albumin and bilirubin from 
baseline were transient; MELD score did not change. An important complication 
relating to the route of cell delivery was a HA dissection during arteriography prior 
to cell delivery. There were no deleterious clinical sequelae and the catheter was 
repositioned to allow cell delivery. Other adverse events included a transient 
cardiomyopathy, a case of eosinophilic fasciitis and HCC development in one 
patient.  
 
BM derived MNCs were compared against CD133 positive cells in 6 patients with 
end stage liver disease (Nikeghbalian, Pournasr et al. 2011). Donor cells were 
delivered via the HPV. There were no significant differences in liver biochemistry or 
adverse events. This raises the possibility of clinical equivalence of the much simpler 
protocol of acquiring the MNC fraction to the costlier and more demanding cell 
sorting process. However, the fundamental priority is to prove that candidate cells 
are indeed efficacious and safe in larger randomised controlled trials. 
 
A randomised controlled trial of MNC therapy was undertaken in 58 patients with 
decompensated cirrhosis due to alcohol excess in Geneva, Switzerland (Spahr, 
Chalandon et al. 2013). The HA delivery of MNCs acquired from BM aspirate after 5 
days of G-CSF priming was tested against standard medical therapy. MELD score 
and hepatic venous pressure gradient improved over time in both groups but there 
was no difference between them. Similarly there were no differences detected in 
histological parameters (of inflammation or LPC number) or serum HGF. The 
proportion of recidivism in each group was not reported (31% overall), this could 
confound the results. Furthermore, the substantial degree of improvement in the 
control arm would make detection of additional benefit from cell therapy potentially 




Conclusions from human studies  
The early studies of autologous BM cell therapy for cirrhosis were small and 
uncontrolled. When carried out in carefully selected patient groups and delivered in 
a controlled manner these have been technically feasible and generally safe. Results 
have been encouraging but not definitive. Subsequently, a number of controlled trials 
have shown evidence of benefit thereby justifying further study. 
 
The natural history of untreated chronic liver disease can involve considerable short 
term variation along an overall downward trend. When the injurious stimulus is 
lifted, for example successful antiviral therapy or cessation of alcohol, liver function 
can markedly improve. Therefore patient circumstance and cirrhosis aetiology need 
to be factored into study design. More, recent trials have examined a single disease 
aetiology.(Peng, Xie et al. 2011; Spahr, Chalandon et al. 2013) (Salama, Zekri et al. 
2010) This permits a clearer assessment of the potential effects of the candidate donor 
cell type in a defined context. Alternatively, large trials can prospectively subgroup 
patients according to aetiology in order to distinguish any differential effects. Given 
the unpredictable episodes of illness that are a feature of decompensated cirrhosis, 
sufficiently large, well-powered trials may be required to detect therapeutic benefit. 
 
HSC populations seem to be safe as a potential cell therapy, however there is still 
little mechanistic understanding of their actions in liver disease. A plausible 
explanation is through paracrine stimulation of the injured liver activating 
endogenous repair. The purity of the donor cell population will reflect its 
effectiveness, practicality and cost. If MNC therapy proves to have similar or even 
superior benefit to more concentrated stem cells, this could facilitate clinical 
translation. The important caveat concerning MSC use is their potential to adopt a 
deleterious phenotype (Russo, Alison et al. 2006; di Bonzo, Ferrero et al. 2008). The 
early direction of MSC differentiation (Kharaziha, Hellstrom et al. 2009) during the 
cell culture process may allow a degree of control of subsequent cell behaviour in 
vivo. Long term phenotypic stability would need to be robustly proven prior to 
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routine use. It may be that cirrhosis is not the optimal disease setting for MSC 
derived cells. As our understanding of the actions of specific cell populations in 
defined settings increases, it is conceivable that the choice of cell type may ultimately 
be tailored to a patient’s disease stage and aetiology. 
 
Serious complications relating to cell injection into the HA or HPV demonstrate the 
importance of the administration route and technique (Mohamadnejad, Namiri et al. 
2007; Salama, Zekri et al. 2010; Couto, Goldenberg et al. 2011). The advantages of 
concentrated cell delivery directly to the liver must be balanced against the ease and 
safety of peripheral venous routes. Insights into the kinetics of donor cells after 
delivery using techniques such as whole body scintigraphy (Couto, Goldenberg et al. 
2011) will help inform this. Transient improvements in liver function have been 
detected in a number of studies.  Repeated cell infusions may be needed to exert 
clinically relevant benefits and achieve substantial disease modification. This has 
implications on the selection of delivery route. In terms of trial design, the delivery of 
inconsistent cell numbers within certain studies limits detection of effect by 
increasing variation and also hampers comparison between studies through potential 
dose related effects. Future work will ideally be standardised. 
 
The most important outcome measures are quality of life and survival. These 
endpoints are affected by the rates of complications, HCC development and need for 
transplantation. The fluctuating nature of cirrhosis means that narrow windows of 
data collection could miss important trends. Serial data collection is therefore useful 
to detect subtle changes. The most convenient are the currently routine blood tests 
(such as PT and serum albumin, liver biochemistry and creatinine). The Child-Pugh 
score is simple to calculate and widely used, though limited by subjectivity in the 
assessment of encephalopathy and ascites. Advantages of the MELD score include its 
objectivity and routine clinical use in transplant prioritisation as a guide to predicted 
survival. The well recognised morbidity and mortality of liver biopsy must be 
weighed against the value of tissue for analysis of both effect and also potential 
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mechanism. Hepatic venous pressure gradient measurement can be undertaken 
alongside trans-jugular liver biopsy. This provides important information relating to 
the risk of complications such as variceal bleeding in addition to prognosis and 
response to therapy (Albilllos and Garcia-Tsao 2011). Biomarkers such as the panel 
of serum markers of liver fibrosis (Rosenberg, Voelker et al. 2004) provide validated 
non-invasive measures of liver fibrosis. Non-invasive tests such as indocyanine green 
clearance and 31P magnetic reasonance spectroscopy (Lim, Patel et al. 2003) are yet to 
reflect outcome reliably and gain widespread acceptance. Therefore at present, a 
panel of surrogate markers is required to provide realistic and achievable goals for 
clinical trials. 
 
In summary, information from experimental animal work regarding the choice of cell 
type, route of delivery and the underlying mechanisms of effect emerging from 
animal work will inform the rational design of human trials. The clinical literature is 
expanding and the next step is for robust randomised controlled trials to test 
clinically useful parameters (Thomas 2013). 
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Table 1.1 Clinical studies of cell therapy for cirrhosis 










Year of publication 






1 x 106 - 2 
x 108 
HA or HPV 
Uncontrolled 
case series 
5 LFTs No No 6-18 
2006, 2008(Gordon, Levicar 













Yes No N/A 
2007(Furst, Schulte am Esch 
et al. 2007) 
CD34+ BM 5.25x106 HA 
Uncontrolled 
case series 
4 MELD No Yes 6 
2007(Mohamadnejad, 








9 CP, LFTs Yes No 3 









48 LFTs Yes Yes 12 














Yes No 6 
2010(Salama, Zekri et al. 
2010) 
MSCs BM 3.1x107 Peripheral 
Uncontrolled 
case series 
4 MELD Yes No 12 
2007(Mohamadnejad, 
Alimoghaddam et al. 2007) 





8 MELD Yes No 6 
2009(Kharaziha, Hellstrom 










52 v 105 
LFTs, MELD, 
survival 
Yes No 12 2011(Peng, Xie et al. 2011)  
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MNCs BM 5.2x109 Peripheral 
Uncontrolled 
case series 
9 CP Yes No 6 










Peripheral Case report 2 CP, MELD Yes No 30 
2006(Yannaki, 
Anagnostopoulos et al. 
2006) 
MNCs BM 3.78x108 HA 
Randomised 
controlled trial 
15 v 15 
CP, MELD, 
LFTs 
Yes No 12 
2010(Lyra, Soares et al. 
2010) 









Yes No 12 2010(Kim, Park et al. 2010) 
MNCs BM 4.4 x107 HA or HPV 
Controlled case 
series 





Yes No 12 
2011(Sharma, Kumar et al. 
2011) 
MNCs BM 2–15x108 HA 
Uncontrolled 
case series 
8 MELD, LFTs Yes Yes 12 













3 v 3 MELD, LFTs No No 24 
2011(Nikeghbalian, 









28 v 30 
MELD, LFTs, 
histology 
No Yes 3 
2013(Spahr, Chalandon et 
al. 2013) 
adapted from Clinical Studies of Cell Therapy for Liver Cirrhosis(Thomas 2013) 
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Animal studies of cell therapy for experimental chronic liver disease 
The most widely used animal models of chronic liver disease have involved iterative 
injury with hepatotoxins such as CCl4. Candidate cells have been given during the 
development of advanced fibrosis. Outcome measures have included blood tests of 
liver function and serum and histological markers of fibrosis, inflammation and 
regeneration. These experimental models of chronic liver disease have indicated that 
rather than attempting to transplant hepatocyte-like cells, a more productive 
therapeutic strategy might be to modulate the underlying pathophysiological 
processes.  
  
A number of cell types have been examined. As described, MSCs have been 
considered an attractive candidate for cell therapy due to their accessibility, 
multipotentiality and immunomodulatory effects. These studies have given 
conflicting results; some have shown a reduction in liver fibrosis following MSC 
delivery whereas other groups have not been able to reproduce this (Zhao, Lei et al. 
2005; Carvalho, Quintanilha et al. 2008; di Bonzo, Ferrero et al. 2008). Considering the 
risk of contributing to myofibroblast like cells (Russo, Alison et al. 2006) given 
current limitations in characterisation and purification, MSCs may not be ideal cell 
populations to treat cirrhosis. One study of MSC therapy published in 2012, 
examined the effects of different routes of cell delivery (Wang, Lian et al. 2012). 
Interestingly, the portal vein but not tail vein administration of MSCs caused 
improvement in liver fibrosis, liver biochemistry and serum albumin. The reasons 
behind this were not explored though the authors suggested that this could relate to 
the effective cell dose reaching the target organ in sufficient concentration. 
 
Sakaida and colleagues have used a Liv-8 depleted BM fraction to reduce hepatic 
fibrosis induced by repetitive CCl4 in mice (Sakaida, Terai et al. 2004). It was 
suggested that the BM derived donor cells might be transdifferentiating into 
hepatocytes however a more likely mechanism may relate to the observed 
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upregulation of MMP-9 expression and localisation of MMP-9 expressing donor cells 
within the scar. HCC is an important complication of cirrhosis with few effective 
treatment options available for the majority of patients. The same group from 
Yamaguchi University Hospital, Japan have also tested BM cells in a model of 
murine liver fibrosis and carcinogenesis (Maeda, Takami et al. 2012). In line with 
human data, the improvement in fibrosis was accompanied by suppressed rates of 
liver cancer formation. Importantly, no cancers were derived from donor (GFP 
positive) elements. 
 
The delivery of exogenous endothelial progenitor cells has also conferred anti-
fibrotic and pro-regenerative effects in rat liver fibrosis (Nakamura, Torimura et al. 
2007). This was associated with increased expression of certain MMPs (-2, -9 and -13) 
and cytokines (such as HGF and VEGF (vascular endothelial growth factor)). Human 
CD34 cells injected into immunodeficient fibrotic rats also caused increased 
expression of MMPs-2, -9 and -13 with a reduction in myofibroblast number and 
fibrosis. There was also evidence of improved hepatocyte regeneration with 
upregulation of restorative cytokines (HGF and VEGF) (Nakamura, Tsutsumi et al. 
2012) .  
 
The delivery of unfractionated BM cells via the tail vein to mice with liver fibrosis 
has recently been shown to reduce hepatic scar (Suh, Kim et al. 2012). Approximately 
75% of the infused BM cells were of myeloid lineage (CD11b, Gr-1 positive) and up 
to 20% possessed the macrophage marker F4/80. The anti-fibrotic effect required 
donor cell IL-10 expression however the donor cell populations were not fractionated 
in this set of experiments. Therefore it is not certain which subset of BM cells, or 
indeed interaction between cell populations, is responsible for the phenotype. 
 
The adoptive transfer of dendritic cells during fibrosis regression after cessation of 
liver injury has been shown to accelerate fibrolysis (Jiao, Sastre et al. 2012). Levels of 
MMP-9 but not MMP-13 were elevated; donor cell derived MMP-9 contributed to the 
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observed phenotype. Of note, different groups have noted apparently divergent 
effects of dendritic cells in liver fibrosis (Connolly, Bedrosian et al. 2010). There is not 
widespread agreement regarding the characterisation of dendritic cells, therefore 
examination of biologically distinct cell types may explain the disparate findings. 
Furthermore, the derivation of the transferred cells involved priming donor mice by 
injection with a melanoma cell line prior to spleen harvest. Splenic cells were then 
fractionated based on cell surface marker profile to obtain the donor dendritic cell 
population. This adds to our understanding of the processes underlying fibrosis and 
its regression. However, the complexity and manipulation required to acquire the 
donor cells make this unlikely to be an easily practicable therapy for patients. As 
with studies of whole BM, various MNC fractions and impure HSC and MSC 
populations, difficulties defining consistent cell populations hamper translation of 
such findings. The use of mixed cell populations also limits the understanding of 
mechanisms of action (Houlihan and Newsome 2008). Therefore the identification of 
defined single cell types with beneficial effects is more likely to inform rational and 
predictable therapy. 
 
Macrophages have a broad repertoire of context dependant immune, inflammatory, 
trophic and regulatory actions (Mantovani, Sica et al. 2004). As described, 
endogenous macrophages mediate hepatic scar remodelling through local MMP 
expression (Duffield, Forbes et al. 2005; Fallowfield, Mizuno et al. 2007). BM 
precursors differentiate into macrophages under the control of colony stimulating 
factor-1 (CSF-1) acting through its receptor (CSF-1R). CSF-1 also controls 
macrophage proliferation, viability and phenotypic fate (Pollard 2009). The delivery 
of exogenous CSF-1 stimulates macrophage infiltration, improving fibrosis and 
function in models of renal (Menke, Iwata et al. 2009) and cardiac (Morimoto, 
Takahashi et al. 2007) injury. Though LPCs are not of BM origin (Vig, Russo et al. 
2006; Lorenzini, Bird et al. 2010) their activation is influenced by a number of 
paracrine signals that represent potential targets for BM derived cell therapy 
(Jakubowski, Ambrose et al. 2005; Bird, Lorenzini et al. 2008). Based on these 
51 
 
findings, we hypothesised that cells from the monocyte-macrophage lineage could 
have utility as a cell therapy in experimental chronic liver disease. 
 
Given this, the experimental aims were to: 
 
1) To study the therapeutic potential of exogenous unmanipulated BM derived 
cells, in particular those of the monocyte-macrophage lineage, delivered 
during chronic liver injury due to repeated CCl4 injury. 
 
2) On identification of a beneficial phenotype following BMM delivery, further 
experiments were to determine potentially mechanistic changes in mediators 
of liver fibrosis and regeneration. 
 
3) To test the effects of BMM therapy in a cholestatic (DDC) model of chronic 
liver disease. 
 











CHAPTER TWO       




















Donor cell preparation and characterisation 
Femurs and tibias were removed from euthanised age-matched, syngeneic male 
mice. These were washed in 70% ethanol. BM cells were then extracted and a single 
cell suspension prepared by passing the cells through a 40 µm filter (BD Falcon).  
 
The Tg(Csf1r-Gfp)Hume (MacGreen) mouse was used in order to isolate macrophage 
precursors from the BM (Sasmono, Oceandy et al. 2003). MacGreen mice used were 
of the balb-c mouse strain background. EGFP expressing cells were gated using 
fluorescence-activated cell sorting (FACS, FACSVantage, Becton and Dickinson). 
These cells will be termed “macrophage precursor cells” in this thesis. 
 
BM derived macrophages (BMMs) were prepared as previously described (Duffield, 
Erwig et al. 2000). DME (Dulbecco’s Modified Eagle)/F12 Glutamax medium was 
conditioned with 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Murine fibrosarcoma cells (L929) which secrete CSF-1 were cultured in 
T162 flasks in 25 ml of the DME medium. The supernatant was harvested 3 days after 
confluency and then filtered, aliquoted and stored at -80°C. This L929 medium was 
subsequently added to the DME media to make 20% L929 medium. BM extracted 
from each femur or tibia was cultured in 40ml of 20% L929 medium in a 90 ml teflon 
pot. These were matured for 7 days; 25% of the medium was replaced on alternate 
days during the process. Diff-Quik staining was performed on cytospin samples to 
characterise the resultant cells. Macrophage surface marker expression was analysed 
by flow cytometry (FACSCalibur, Becton and Dickinson). Cells were stained using 
the following pre-conjugated antibodies: F4/80, CD11b (eBiosciences), Ly-6G 
(Biolegend), Ly-6C, CD3 and CD19 (BD Pharmingen) with the appropriate isotype 
controls.  
 
The traditional categorisation of macrophage phenotypes has been into the classical 
or alternatively activated states. In order to characterise unstimulated (naïve) BMMs  
54 
 
in this context, BMMs were polarised for the purposes of phenotypic comparison, 
Classically activated (M1) macrophages were generated by overnight stimulation 
with lipopolysaccharide (Sigma, 50 ng/ml) and interferon-γ (Peprotech, 20 ng/ml).  
Alternatively activated (M2) macrophages were produced by stimulation with IL-4 
and IL-13 (both Peprotech, 20 ng/ml) (Mantovani, Sica et al. 2004). 
To test the effect of nonviable, physically disrupted BMMs, these were sonicated 
using a Bandelin sonicator (Bandelin) - twice for 10 seconds at a 50% power setting. 
Recipient disease models 
Wild type rodents were supplied by Harlan (UK). Rodents were housed in a sterile 
animal facility with a 12 hour dark/light cycle and free access to food and water. All 
animal experiments were carried out under procedural and ethical guidelines of the 
British Home Office.  
Preliminary work in collaboration with Dr Caroline Pope tested the effects of twice 
weekly intraperitoneal (IP) injection of 1mg/kg CCl4 (dissolved in sterile olive oil) 
given to adult female Sprague-Dawley rats over 12 weeks. Rats were euthanised after 
8, 10 and 12 weeks of injury. Upon confirmation of safe administration and the 
histological progression of liver fibrosis with increasing CCl4 exposure (appendix 
two) subsequent work focused on murine liver fibrosis as detailed below. Advanced 
liver fibrosis was induced in adult female mice by either iterative intraperitoneal 
CCl4 injection or administration of the diethyl 1, 4-dihydro-2, 4, 6-trimethyl-3,5-
pyridinedicarboxylate (DDC) diet. 
1) Carbon tetrachloride injection 
Twice weekly intraperitoneal (IP) injection of 0.75 ml/kg CCl4 dissolved in 
sterile olive oil was given over a 10 week period. One day after the 12th CCl4 
injection (6 weeks), mice from the same cohort were randomly allocated to 
receive either cell or control medium injections via the HPV. To examine the 
early effects of cell delivery, separate experiments were undertaken with 
mouse groups being euthanised at 10 minutes, 1, 6 and 12 hours and 1, 3 and 
7 days after cell/control medium delivery. 
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In order to determine the effects of different CCl4 dose and experimental 
duration in addition to an alternative route of cell delivery, further 
experiments were performed using:  
i) 12 weeks of twice weekly IP 0.4 ml/kg CCl4 dissolved in sterile olive 
oil with cell/control delivery 1 day after the 16th CCl4 injection (8 
weeks) 
ii) delivery of cells/control medium via the tail vein 
iii) repeated administration of cells/control medium via the tail vein (4 
doses over the final 4 weeks of injury); each cell/control medium 
injection was performed 1 day after the preceding CCl4 injection. 
Transgenic mice were used to allow donor cell tracking and selection of 
specific subpopulations of BM cells. Recipient mice were of the same strain as 
donors to ensure syngeneic cell transfer. C57Bl/6 (wild type), CBA/Ca (for 
constitutive GFP expression (Pratt, Sharp et al. 2000)) and balb-c (for 
conditionally enhanced GFP expressing macrophage precursor cells 
(Sasmono, Oceandy et al. 2003)) strains were used. 
 
2) Diethyl 1, 4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC) diet 
S129 S2 mice were fed a diet with 1% DDC (by weight) ad libitum for 5 weeks. 
After 3 weeks of injury they received either cell or control medium injections 
via the HPV. The mice then continued on the DDC diet until euthanisation at 5 
weeks. 
 
C57Bl/6 mice were used for most experiments. As donor and recipient mice were 
syngeneic, additional strains were required for certain experiments: CBA/Ca mice 
were used for GFP positive donor BMM tracking and balb-c mice for macrophage 
precursor selection. S129 S2 mice were used for the DDC model as this toxic diet was 
tolerated by this strain but had proved deleterious in others when used in our group 




Donor cells from age and strain-matched mice were suspended in 100 µl of DME 
medium.  Cells were administered via either the hepatic portal vein (HPV) or tail 
vein (TV): 
1) The HPV was accessed by midline laparotomy using aseptic technique. 
Anaesthesia was induced using 1 mg/kg medetomidine and 76 mg/kg 
ketamine (IP). 22.5 mcg/kg buprenorphine (SC) was given as analgesia. 
Careful identification of the HPV and injection of cell suspension/control 
medium under direct vision was promptly followed by haemostasis using 
sterile Surgicel (Ethicon). Following surgical closure of the abdomen, 
anaesthesia was reversed with 1 mg/kg atipamezole given subcutaneously 
(SC).  
2) The TV was identified in unanaesthetised, restrained mice and injected under 
direct vision.  
 
Tissue harvest and preservation 
Rodents were venesected at euthanisation. Liver, spleen, lungs and kidneys were 
removed and split for freezing or fixation. Organ pieces were snap frozen either 
alone or in Tissue-Tek OCT Compound (Sakura Finetek) in a sterile container on 
100% ethanol in dry ice until the OCT had set. Further samples were fixed in 
buffered formalin (10 ml 37% formalin in 100ml PBS) or methacarn (70 ml methanol, 
20 ml chloroform and 10 ml acetic acid). Fixed tissue was then dehydrated and stored 





Collagen staining and immunohistochemistry 
Prior to staining, tissue sections were dewaxed in xylene for 10 minutes at room 
temperature and then rehydrated sequentially through 100%, 75% and 60% ethanol 
(5 minutes each step). Sections were then rehydrated in water for 10 minutes. 
 
For picrosirius red (PSR) staining, sections were immersed in picrosirius red solution 
(Sigma, UK) and incubated for 60 minutes. Slides were then washed in water before 
sequentially dehydrating in alcohol (50 to 100%) and finally xylene before mounting 
in Pertex hard medium. 
 
For immunostaining, sections were dewaxed and rehydrated as described. If 
required, an antigen retrieval step was performed (table 2.1). Sections were then 
washed in phosphate buffered saline (PBS) prior to quenching of endogenous 
peroxidases by incubation in 1% hydrogen peroxide solution for 10 minutes. Sections 
were washed with PBS and mounted into Sequenza racks. An avidin/biotin blocking 
kit (DAKO) was used to block endogenous activity (15 minute incubations with PBS 
washes). Species specific serum (20%) was used to block non-specific binding of the 
secondary antibody by incubation for 30 minutes. Following this, sections were 
incubated with the primary antibody made up in antibody diluent (DAKO) (as per 
table 2.1) for 60 minutes at room temperature. Appropriate isotype controls were 
used for each primary antibody. After a further set of PBS washes, sections were 
incubated with biotinylated secondary antibody (1:400 dilution) for 30 minutes. 
Vector RTU reagent was then applied (30 minute incubation) following which slides 
were developed for 3 minutes using 3, 3'-diaminobenzidine (Dako) and then 
counterstained for 10 seconds with Harris’ haematoxylin. Slides were then washed in 
water before sequentially dehydrating in alcohol (50 to 100%) and finally xylene 
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Dual staining was used to determine the cellular source of MMP-9 in liver sections. 
Frozen sections were stained with MMP-9 and F4/80 or Ly-6G, which were detected 
with Alexa Fluor 488, 546 and 555 (Invitrogen) respectively. These slides were then 
mounted using Vectashield with DAPI (Vector Laboratories).  
 
TUNEL staining (Promega) was performed on formalin fixed liver tissue as per the 
manufacturer’s instructions. Briefly, following dewaxing, rehydration and 
permeabilisation using 20 µg/ml proteinase K, sections were incubated with the 
manufacturer’s equilibration buffer with recombinant terminal deoxynucleotidyl 
transferase and a nucleotide mix. A DAPI nuclear stain in Vectashield mounting 
medium was used prior to fluorescent visualisation of apoptotic cells. Dual staining 
for α-SMA was visualised with streptavidin-Alexa Fluor 555 (Invitrogen). 
 
Male cells were detected by Y chromosome fluorescent in situ hybridization (FISH) 
using FITC-labelled Y-chromosome paint (Star-FISH; Cambio), as previously 
described (Russo, Alison et al. 2006). Briefly, following dewaxing with xylene and 
rehydration through graded alcohols to water, liver sections were incubated in 1 M 
sodium thiocyanate at 80°C for 10 minutes. Following PBS washes, sections 
underwent proteolytic digestion (0.4% pepsin in 0.1 M HCl at 37°C) for 10 minutes 
before quenching with glycine (0.2% vol/wt). After further PBS washes, sections were 
postfixed in paraformaldehyde solution and then dehydrated through graded 
alcohols before air drying. The manufacturer’s Y chromosome paint mix was applied 
to the sections which were then sealed under a coverslip with rubber cement and 
heated to 60°C for 10 minutes. The slides were then allowed to hybridise overnight at 
37°C. The next day, the coverslips were removed and the slides rinsed in 0.5xSSC 
and then PBS before mounting in Vectashield with DAPI (Vector Laboratories). 




Assessment of tissue sections 
Stained slides were blinded and randomised prior to microscopy and photographing 
for quantification. Prior publications from our group that had used histological 
quantification of liver sections to examine these parameters used 10 images at x200 
magnification (Fallowfield, Mizuno et al. 2007) and at least 10 images at x100 
magnification (Duffield, Forbes et al. 2005). In order to facilitate identification of cells 
when counting, the higher x200 magnification was chosen. For comparison, a similar 
study of cell therapy for liver fibrosis by a different group had used only 6 images at 
x200 magnification (Nakamura, Torimura et al. 2007). The accuracy of the results 
increases with the number of images examined, however this must be balanced 
against the need for a practicable and efficient method. Use of a rolling mean of 
quantification scores had shown that achieving a minimum of 20 serial, non-
overlapping fields at x200 magnification covered at least as large an area of liver 
tissue as in this recent literature whilst producing accurate data; therefore this 
method was adopted. 
 
Male donor cells were detected by FISH for the Y chromosome. As not all male cells 
in a tissue section will have an exposed nucleus, the amount of Y chromosome probe 
binding will underrepresent the number of male cells. Therefore a correction 
coefficient was determined using male liver tissue. The proportion of non-
parenchymal cells in male sections that bound the probe was established (54%). This 
allowed adjustment of subsequent counts to determine the total number of male 
donor cells present within female liver sections. 
 
In order to quantify the number of F4/80, Ly-6G, GFP, MMP-9 and MMP-13 
expressing cells, the number of positively stained cells per high power field was 
counted using Image J software (National Institutes of Health). Proliferating 
hepatocytes were identified as parenchymal cells with hepatocytic morphology and 




Pancytokeratin (PCK) has been validated as a marker of murine LPCs (Kofman, 
Morgan et al. 2005). Though considered sensitive for progenitor cells, this antigen is 
not specific as PCK is also a marker of biliary epithelia. As per Oben et al (Oben, 
Roskams et al. 2003) and Kofman et al (Kofman, Morgan et al. 2005), the consensus in 
the field is that LPCs can be more selectively detected by considering the location 
and morphology of these cells in addition to their expression of cytokeratin. These 
and subsequent studies (e.g. (Van Hul, Lanthier et al. 2011), (Bird, Lu et al. 2013)) 
defined LPCs as also being small oval/cuboidal cells with a high nuclear to 
cytoplasmic ratio, importantly, cells with hepatocyte like morphology and low 
nuclear to cytoplasmic ratio and also small cells directly abutting a lumen 
(considered bile duct cells) were excluded. This could potentially result in missing 
LPCs which are indistinguishable from the bile duct due to the two dimensional 
nature of histological sections however this method prevents incorrectly including 
cholangiocytes. Furthermore, the majority of LPCs are clearly distinct from the bile 
duct and so would be counted. To date, a fully sensitive and specific LPC marker has 
not been identified therefore this method combining cell marker, topography and 
morphology represents the current standard in the literature. 
 
In order to quantify the amount of α-SMA, collagen I and PSR staining, the 
photomicrographs were processed using image analysis software (Adobe 
Photoshop). This produced a measurement of the area of staining; the percentage 
staining was calculated by using the total field area as the denominator. To allow for 
differences in staining intensity between different batches, all sections from the same 
experimental group were stained together under the same conditions. In order to 
compare across experimental groups, these measurements are expressed relative to 





Frozen whole liver samples (approximately 0.1cm3) were placed in 300 µl of Tissue 
Protein Extraction Reagent (TPER) (Pierce).  The sample was then disrupted by 
repeated passage through a 19 gauge needle, sonicated and centrifuged (at 12 000 
rpm) for 10 minutes.  The supernatant was then removed to determine the protein 
concentration by modified Bradford assay (Bradford 1976). 5 µl of protein extract 
was added to 150 µl of Bradford Reagent (Sigma) and 155 µl of distilled 
water. Bovine serum albumin (Sigma) was diluted to generate reference 
standards. Absorbance was measured at 595nm using a Biotek Synergy HT 
microplate reader (Biotek). 
 
Multiplex cytokine assays for KC, MCP-1 (macrophage chemoattractant protein-1), 
MIP-1α (macrophage inflammatory protein-1α), MIP-2, IL-6, IL-10, TNFα, VEGF and 
CSF-1 were performed using the Bio-Plex Pro Magnetic Cytokine Assay kit on the 
Bio-Plex 200 Suspension Array system and Bio-Plex Pro Wash Station (Bio-Rad) in 
collaboration with Dr Tim Gordon-Walker. Cytokine assays were performed 
according to the manufacturer’s instructions. Test samples were diluted to a 
concentration of 10 mg/ml, eight standards in addition to blank wells (to determine 
background fluorescence) were used; all measurements were in duplicate. Per well, 
50 µl of sample was incubated with magnetic beads (conjugated to the capture 
antibody of interest) for 30 minutes at room temperature.  Samples were then 
washed 3 times in 100 µl of Bio-Rad Wash buffer (Bio-Rad).  The biotinylated 
detection antibody was then added to samples and incubated for 30 minutes at room 
temperature. After a further wash step (3 times in 100µl of Bio-Rad Wash buffer (Bio-
Rad)), the samples were incubated with the streptavidin-conjugated phycoerythrin 
reporter for 10 minutes at room temperature.  The samples were again washed as 
previously before resuspension in Bio-Rad Assay buffer (Bio-Rad).  This mixture was 
then analysed on the Bio-Plex 200 Suspension Array system using Bio-Plex Manager 
3.0 software (Bio-Rad) and the concentration of each target protein calculated against 
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the standard curve.  Final protein concentrations are expressed relative to matched 
control samples from the same time point.  
Serum biochemistry measurements were performed independently by the Specialist 
Assay Service run by Dr Forbes Howie (Centre for Reproductive Medicine) using the 
Roche Cobas Fara Centrifugal Analyser. Commercial kits for serum albumin (Randox 
Laboratories Ltd) and ALT and bilirubin (Alpha Laboratories Ltd) were used. 
Successful venesection requires aspiration of blood at the time of euthanisation but 
before cardiac death. In addition to this relatively narrow window for venesection, 
the small calibre of needle required to cannulate murine vessels can cause sample 
haemolysis. Therefore adequate samples were not obtained from all subjects.  
 
Hydroxyproline assay  
Snap frozen liver samples (approximately 200 mg) were weighed and homogenised 
prior to hydrolysing in 2N sodium hydroxide at 120°C for 20 minutes. The 
hydrolysed samples were then mixed with acetate-citrate buffered chloramine T 
reagent (0.056M) and allowed to oxidise at room temperature for 25 minutes. 
Ehrlich’s aldehyde reagent was then added prior to incubation at 65°C for 20 
minutes. Absorbance was measured at 550 nm using a spectrophotometer and 
hydroxyproline content expressed as µg/g liver (Reddy and Enwemeka 1996).  
 
Quantification of mRNA levels by Real Time Reverse-Transcription 
Polymerase Chain Reaction 
RNA was extracted from whole liver tissue using RNA extraction kits (RNeasy mini 
kit, Qiagen) according to the manufacturer’s instructions. Briefly, approximately 30 
mg of frozen liver tissue was added to 600 µl of buffer RLT (with 10 µl/ml β-
mercaptoethanol added) disrupted and then homogenised using the QIAshredder 
microfuge column (Qiagen). The lysate was centrifuged at high speed for 3 minutes 
64 
 
and the resulting supernatant was mixed with an equal volume of 70% ethanol 
before transferring to an RNeasy spin column (Qiagen) to centrifuge for 15 seconds 
at 10 000 rpm. The column was then washed firstly by the addition of 700 µl of RW1 
buffer and centrifugation for 15 seconds at 10 000 rpm. 500 µl of RPE buffer was then 
used to wash the column by further centrifugation for 15 seconds at 10 000 rpm. This 
was then repeated with another 500 µl of RPE buffer for a longer centrifugation of 2 
minutes. The RNA was then eluted from the column by adding 50 µl of RNase-free 
water directly to the column membrane and centrifuging for 1 minute at 10 000 rpm. 
The resulting concentration of RNA was measured using a NanoDrop (Thermo 
Fisher). 
 
Complementary DNA was reverse transcribed from 1 µg of RNA using the 
Superscript II kit (Invitrogen) according to the manufacturer’s instructions. Briefly, 
per sample, 0.8 µl DNAse I solution, 1 µl 10x DNAse reaction buffer and 
DNAse/RNAse free water were added to 1 µg of RNA to make a total volume of 8.2 
µl. After 15 minutes at room temperature, 0.8 µl of 25 nM EDTA solution was added 
prior to heating to 65°C for 10 minutes. Each 20 µl reaction also included 2 µg (in 2 
µl) of random hexamers, 4 µl of 5xRT buffer, 0.5 µl of 10mM dNTP mix, 2 µl of 0.1 M 
DTT, 0.5 µl of Superscript II, 0.5 µl of RNAse inhibitor and 1.5 µl of DNAse/RNAse 
free water. The reaction was carried out at 37°C for 60 minutes before inactivation 
and storage. 
 
Primers for MMPs-2, 9, 12 and 13, Fizz-1, IL-10, inducible nitric oxide synthase 
(iNOS), MCP-1, mannose receptor, TNF-α and Ym-1 were designed using primer 
express software (table 2-2). Predesigned, validated primer sets for macrophage 
inflammatory protein (MIP)-1α, MIP-2, KC, MMP-8, HGF, insulin-like growth factor-
1 (IGF-1), CK-19 and TWEAK were purchased from Qiagen (UK). A predesigned, 
validated eukaryotic 18S primer/probe set (Applied Biosystems) was used as the 




Equal amounts of cDNA from each sample were combined and diluted 1:9 in 
DNAse/RNAse free water to generate a standard which was then serially diluted 1:1 
to produce 7 reference standards. Test samples of cDNA were diluted 1:100 for 
analysis. 10 µl of reaction mixture per well of the optical plate contained 4 µl of 
diluted cDNA, 5 µl of SYBR Green Master Mix (Qiagen) and 1 µl of primer mix. All 
reactions were performed in triplicate. The reaction conditions were 1 cycle of 95oC 
for 20 seconds to activate DNA polymerase and then 40 cycles of denaturation (95oC 
for 3 seconds) and annealing/extension (60oC for 30 seconds) on an ABI 7500 Fast 
Real Time PCR system (Applied Biosystems). Where primer probe sequences were 
used (table 2.2), TaqMan Express qPCR Supermix (Invitrogen) was used as per 
manufacturer’s instructions. Gene expression was internally controlled by measuring 
expression of ribosomal 18S in the same sample. These standardised results are 





Table 2.2 Primer sequences designed using primer express software 
Gene Orientation Sequence 
MMP-2 forward 5’-AACTACGATGACCGGAAGTG-3’ 
reverse 5’-TGGCATGGCCGAACTCA-3’ 
probe 5’-TCTGTCCTGACCAAGGATATAGCCTATTCCTCG-3 
MMP-9 forward 5’-CGAACTTCGACACTGACAAGAAGT-3’ 
reverse 5’-GCACGCTGGAATGATCTAAGC-3’ 
probe 5’-TCTGTCCAGACCAAGGGTACAGCCTGTTC-3’ 
MMP-12 forward 5’-GAAACCCCCATCCTTGACAA-3’ 
reverse 5’-TTCCACCAGAAGAACCAGTCTTTAA-3’ 
probe 5’-AGTCCATCAACTTTCTGTCACCAAAGC-3’ 
MMP-13 forward 5’-GGGCTCTGAATGGTTATGACATTC-3’ 
reverse 5’-AGCGCTCAGTCTCTTCACCTCTT-3’ 
probe 5’-AAGGTTATCCCAGAAAAATATCTGACCTGGGATTC-3’ 
Fizz-1 forward 5’-TACTTGCAACTGCCTGTGCTTACT-3’ 
reverse 5’-TATCAAAGCTGGGTTCTCCACCTC-3’ 
IL-10 forward 5’-TGCAGGACTTTAAGGGTTACTTGG-3’ 
reverse 5’-CAGGGAATTCAAATGCTCCTTG-3’ 



















Statistical support for data analysis was received from Justin Scott (statistician, 
University of Queensland): parametric data were analysed by 2 tailed Student’s t test 
whilst Mann-Whitney U test was used for non-parametric data and data are 
presented as mean ± standard error of the mean, unless otherwise stated. These 
calculations were conducted using Prism by GraphPad Software Inc. Statistical 
analysis was performed on absolute values. 
 
As explained in “Assessment of tissue sections”, inter-experimental variables in 
particular tissue staining intensity were controlled for by comparing samples with 
matched controls stained in the same run. Therefore measurements of effect in a 
treatment group were only directly analysed against the matched controls from the 
same experiment. In order to represent temporal trends between different 
experiments graphically, measurements from each experiment are expressed relative 
to the specific time-matched control. Mathematically, each data point within an 
individual experiment (treatment and control) was divided by the mean value of the 
control group thereby expressing the treatment effect as a ratio of its matched control 
and preserving the relative distributions therefore including error bars.  
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CHAPTER THREE        
Characterisation and selection of 






As described, a number of groups have found potential benefits of BM cell therapy 
for liver disease in human subjects and also murine models. In order to inform the 
rational design of clinical studies, the aim of this project was to determine which cell 
types might have beneficial effects in experimental models and to explore the 
underlying mechanism(s). 
 
Given the lack of clarity regarding the precise cell populations used in the literature, 
a hierarchical approach was taken to allow the accurate delineation of candidate 
donor BM derived cells in a logical manner. Considering the theoretical basis for 
macrophages having potential as cell therapy (Sakaida, Terai et al. 2004; Duffield, 
Forbes et al. 2005), BM was fractionated by lineage. Candidate cells included whole 
BM, those BM cells with the capacity to differentiate into macrophages (“macrophage 
precursor cells”) and the differentiated macrophages (BMMs) themselves. By using 
clearly defined cell types and examining their effects when applied to experimental 
models, I aimed to investigate their utility as therapeutic agents. Well characterised 
BM cell populations were used in order to improve mechanistic understanding and 
facilitate subsequent translation to the clinic. 
 
The aim of this chapter is to describe the different outcomes of the candidate donor 




Characterisation of candidate bone marrow cell types 
Whole (unfractionated) bone marrow contains heterogeneous populations of cells. 
These include HSCs, myelopoietic and erythropoietic cells and stromal cells 
(including MSCs, endothelial cells and their progenitors and fibroblasts) in addition 
to lymphocytes, plasma cells, megakaryocytes and reticular cells (Yang, Busche et al. 
2013). As previously discussed, some of these cells e.g. MSCs (Russo, Alison et al. 
2006; di Bonzo, Ferrero et al. 2008) and fibroblasts, could have fibrogenic effects and 
thus be deleterious in the therapeutic context. A subset of the BM is comprised of 
cells with the potential to differentiate into macrophages. The differentiation of BM 
progenitors into macrophages is controlled by the lineage restricted growth factor, 
CSF-1. CSF-1 (also known as macrophage colony stimulating factor (M-CSF)) 
promotes macrophage differentiation through binding to the cell surface receptor 
(CSF-1R). CSF-1R is encoded by the c-fms gene. Sasmono and colleagues developed 
transgenic mice with an EGFP reporter gene under the control of the c-fms promoter 
(termed MacGreen mice). This allows detection of BM cells with the capacity to 
respond to CSF-1 stimulation and therefore develop into macrophages in the correct 
circumstances. Flow cytometric analysis of MacGreen mouse BM shows that EGFP 
co-localises with CD11b indicating that transgene expression is confined to myeloid 
cells. Approximately 50% of EGFP positive BM cells express F4/80 or CSF-1R protein 
(Sasmono, Oceandy et al. 2003).  
 
Interestingly, subsequent work by the same group showed that EGFP expression was 
not restricted to macrophages. Neutrophils (marked by the Ly-6G antigen) also 
expressed the EGFP reporter indicating transcription of the CSF-1R gene. 
Neutrophils have previously been shown to undergo a lineage switch to cells with 
the morphological, cytochemical and phenotypic characteristics of macrophages 
under the influence of CSF-1 (Araki, Katayama et al. 2004). Of particular relevance, 
Sasmono and colleagues went on to demonstrate that the 7 day in vitro culture of 
murine neutrophils with CSF-1 results in their transdifferentiation into mature F4/80 
positive macrophages (Sasmono, Ehrnsperger et al. 2007). FACS was used to separate 
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the EGFP expressing cells from the BM of MacGreen mice (figure 3.1A) thereby 
selecting potential macrophage precursor cells. There appear to be two populations 
of EGFP expressing BM cells in figure 3.1A. Whilst these EGFP positive cells all have 
the potential to differentiate into macrophages upon stimulation with CSF-1, this 
may reflect differential CSF-1R promoter activity between granulocytes and 
mononuclear cells. 
 
In contrast to the potential macrophage precursor cells fluorescently sorted from the 
BM of MacGreen mice, differentiated BMMs were cultured in non-adherent 
conditions for 7 days. BMMs produced in this way are recognised as naïve 
(unstimulated) macrophages. The photomicrograph of the BMM cytospin Diff-Quik 
stain shows that the majority of these cells were morphologically homogenous 
(figure 3.1B). Further characterisation by flow cytometry demonstrated that BMMs 
expressed the conventional macrophage markers of F4/80 and CD11b (Hume 2006) 
without significant contamination by Ly-6C positive monocytes, Ly-6G positive 
neutrophils, CD3 positive T lymphocytes or CD19 positive B lymphocytes (figure 
3.1C). The gene expression of a panel of phenotypic activation markers was 
measured in order to consider unstimulated BMMs in the traditional paradigm of the 
classically (M1) and alternatively (M2) activated macrophage (Mosser and Edwards 
2008) (figure 3.2A). These results are from collaboration with Stephen Hartland and 
Marielle Van Deemter. In comparison with macrophages deliberately stimulated to 
develop the polarised M1 and M2 phenotypes, naïve BMMs do not fit clearly into 
either classification (figure 3.2B). Donor BMMs expressed a number of factors with 











Figure 3.1 Characterisation of candidate donor cells 
 




Figure 3.1 Characterisation of candidate donor cells 
(A) MacGreen mouse BM cells expressing the CSF-1 receptor/EGFP transgene are 
potential macrophage precursors. These cells were positively selected by FACS 
(denoted “EGFP+ macrophage precursor cells”).  
(B i) Macrophages were differentiated from whole BM cultured for 1 week in CSF-1 
conditioned media. Diff-Quik staining of cytospins of these cells demonstrates that 
they are mononuclear with the characteristic staining profile of violet nuclei with 
light blue cytoplasm. Original magnification, x200. B ii shows a cytospin under 
higher effective magnification (x400) allowing clearer visualisation of the 
morphological heterogeneity.  
(C) Flow cytometric analysis demonstrated that BMMs possessed the typical 
macrophage markers F4/80 and CD11b. The donor BMMs were relatively pure; 
markers of other leukocyte populations (monocytes, neutrophils and T and B cells) 
were minimally detected. This histogram was derived from the data in figure D. 
(D) Original flow cytometry plots determining BMM surface marker expression. 
CD11b - F4/80 co-positive cells were in gate R3, positive cells in the single 
fluorochrome assessments were gated as R1. Flow cytometry was done in 




Figure 3.2 Donor BMMs are phenotypically intermediate between 




Figure 3.2 Donor BMMs are phenotypically intermediate between 
classically and alternatively activated macrophages 
(A, B) BMMs were stimulated by in vitro incubation with lipopolysaccharide and 
interferon-γ or IL-4 and IL-13 to polarise them to the traditional classically (M1) or 
alternatively (M2) activated phenotype respectively. Unstimulated (naïve) BMMs 
were then examined in this context. Gene expression analysis of classical and 
alternative macrophage activation markers demonstrated that BMMs did not 
conform to either phenotype in this regard. These figures are descriptive therefore no 
statistical analysis was performed; n=3 per group. Data in collaboration with Stephen 





Table 3.1 Pre-injection BMMs expressed anti-inflammatory, anti-fibrotic, 
pro-regenerative and chemotactic mediators 
 






   





















IL-10 2.2 6.5 +/- 1.5 5 2.9 +/- 2.4 5 0.15   (MW) 
MMP-13 38.4 14.6 +/- 3.0 5 0.4 +/- 0.04 5 <0.01 (S) 
TWEAK 20.7 17.6 +/- 2.8 5 0.8 +/- 0.1 5 <0.01 (S) 
MCP-1 75.6 19.4 +/- 4.1 5 0.3 +/- 0.03 5 <0.01 (S) 
MIP-1α 668.9 42.7 +/-10.1 5 0.1+/- 0.004 5 <0.01 (S) 
MIP-2 77.6 20.3 +/- 3.2 5 0.3 +/- 0.2 5 <0.01 (MW) 




Cells of the monocyte-macrophage lineage have differential effects 
on liver fibrosis 
1 x 106 candidate donor BM derived cells were delivered via the HPV 6 weeks into a 
10 week CCl4 injury protocol. Mice were then euthanised and tissue harvested for 
analysis. The schematic below demonstrates the time course of the experiment 
(figure 3.3). 
 
Figure 3.3 Schematic of CCl4 experimental protocol testing candidate 
donor BM cells 
  
 
4 weeks after the injection of 1 x 106 whole BM cells, there was an increase in liver 
fibrosis measured by PSR quantification. Whole BM cell recipient mice had 161% 
more fibrosis than controls (P < .05, figure 3.4A, B). In contrast to this pro-fibrogenic 
effect, injecting 1 x 106 macrophage precursor cells did not significantly change the 
amount of fibrosis (P = .21, figure 3.4A, B). The same number of BMMs however 













Figure 3.4 BM derived cell populations have differential effects on liver 
fibrosis 
Advanced liver fibrosis was induced in adult female mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Photomicrographs show PSR staining for fibrillar collagens 4 weeks after the 
intraportal delivery of 1 x 106 syngeneic whole (unfractionated) BM, macrophage 
precursor cells or wild type BMMs (right sided column). Age and strain-matched 
mice within each cohort received an equal volume of control medium (left sided 
column). As stated in the Methods, macrophage precursor cells were obtained from 
the BM of MacGreen mice on a balb-c background therefore these cells were 
delivered to fibrotic balb-c recipients. Whole BM and BMMs were obtained from 
C57Bl/6 mice and therefore delivered to C57Bl/6 mice.  Original magnification, x80. 
(B) Morphometric analysis of PSR staining revealed that the application of whole BM 
increased the amount of fibrosis. BM macrophage precursor cells did not 
significantly change the amount of fibrosis. Treatment with differentiated BMMs 
caused a reduction in liver scarring. (* P < .05 compared with control recipients; n=6-7 
per group). These histograms are derived from the data in table 3.2 below. Within 
each separate experiment, all values are expressed as a ratio of the mean of the 
internal control group. This allows a graphical comparison of the magnitude of 





Table 3.2 BM derived cell populations have differential effects on liver 
fibrosis  
Candidate cell type 
 





Mean  +/- SEM 
4.9 +/- 0.5 9.7 +/- 1.3 7.2 +/- 0.7 
Control  
N 
6 6 7 
Candidate cell 
PSR % 
Mean  +/- SEM 
7.9 +/- 1.0 7.7 +/- 0.8 4.8 +/- 0.4 
Candidate cell 
N 
6 7 6 
P value 
(S = Student’s t test) 







BMM delivery improves liver fibrosis and serum albumin levels 
Given the reduction in PSR staining following the injection of BMMs, subsequent 
experiments focused on specifically examining this phenotype with regard to its 
translational potential. Additional methods of scar quantification were employed to 
confirm the magnitude of effect from BMM delivery. Hydroxyproline is a post-
translational product of the hydroxylation of the amino acid proline and a key 
component of collagen (Reddy and Enwemeka 1996). Hydroxyproline assay carried 
out on approximately 200mg pieces of liver demonstrated a similar magnitude 
decrease in liver collagen following BMM therapy (368.2 ±41.0 v 558.8 ±94.6 µg/g 
liver, P = .05, figure 3.5A). Specific immunostaining for collagen I was quantified 
using image analysis, this also confirmed a comparable improvement in BMM 
recipients (73% of control, P < .01, figure 3.5B, C).  These data support the PSR 
morphometric analysis (figure 3.4) detecting an approximately 1/3 reduction in liver 









Figure 3.5 BMM therapy causes a reduction in liver fibrosis 
Following identification of the anti-fibrotic effect of BMMs, further experiments 
using alternative measures of scar quantification were undertaken to confirm the 
magnitude of this effect. Advanced liver fibrosis was induced in adult female 
C57Bl/6 mice by administration of twice weekly IP CCl4. The reduction in liver 
fibrosis 4 weeks after the intraportal delivery of 1 x 106 BMMs was confirmed by (A) 
hydroxyproline assay and (B) collagen I immunostaining (original magnification, 
x80) with (C) morphometric analysis and quantification. (* P ≤ .05, ** P < .01 by 1 
tailed analysis compared with control recipients; n=6-7 per group). This histogram is 
derived from the data in table 3.3 below; all values are expressed as a ratio of the 
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In addition to determining the impact of the candidate BM derived donor cells on 
liver fibrosis, serum was also taken at the time of euthanisation 4 weeks after cell 
injection to measure albumin and bilirubin levels. These tests are routinely used as 
indicators of “liver function” in the clinical setting. 
 
It is important to note that there is group to group variability between cohorts of 
CCl4 treated mice. This is likely to be mostly attributable to differences between 
mouse strains. In addition, there may well be minor variations in housing conditions, 
composition and delivery of CCl4 and potentially host factors even within an inbred 
strain. This was addressed by using inbred strains of mice housed in the same rooms 
within one animal facility and only directly comparing the effects of intervention 
against control within the same mouse cohort (as opposed to between). 
 
Neither the delivery of whole BM (36.0 ± 0.6 v 36.5 ± 0.5 g/L) nor macrophage 
precursor cells (42.2 ± 3.3 v 39.4 ± 0.5 g/L) significantly affected serum albumin levels. 
However, BMM therapy resulted in an increase in serum albumin from 39.9 ± 0.9 g/L 
in the control group to 46 ± 2.6 g/L post treatment (figure 3.6A). Albumin is 
synthesised by the liver. Low serum levels can indicate reduced hepatic synthetic 
function therefore serum albumin is a marker of liver regeneration. Serum albumin 
in also an acute phase marker, therefore laparotomy at the time of HPV cell injection 
could also affect this. For reference, normal adult murine albumin is ~40 g/L 
(Fernandez, Pena et al. 2010). Mice that received iterative CCl4 but did not undergo 
surgery had a mean serum albumin of 39.5 g/L (figure 5.4C). This suggests that the 
CCl4 induced injury was not sufficiently severe to cause liver decompensation with 
associated low serum albumin levels. Furthermore, if surgery did cause a reduction 
in serum albumin in this context, then this effect was transient as it was not apparent 
4 weeks later at the time of harvest. Though baseline albumin levels were not 
significantly suppressed, the additional increase in serum albumin following BMM 
therapy suggests a pro-regenerative stimulus. This is consistent with work 
examining the peripheral delivery of BMMs to normal (uninjured) mice. (Bird, Lu et 
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al. 2013) In this setting, in the absence of surgery or liver injury, BMM injection 
caused LPC expansion via TWEAK signalling and increased serum albumin levels 
indicating enhanced liver function.  
 
Serum bilirubin measurements were obtained following the application of whole BM 
and differentiated BMMs. Consistent with the increase in fibrosis following BM 
delivery, there was a significant rise in serum bilirubin (7. 7 ± 0. 9 v 11.8 ± 1.5 µmol/L) 
in the whole BM recipients. Serum bilirubin levels were not elevated in either the 
control or BMM treatment groups (figure 3.6B). 
 
The results of these serum measurements in conjunction with the improvement in 
liver fibrosis indicated a potentially beneficial phenotype following BMM delivery. 
Therefore, subsequent experiments focused on exploring the nature of these effects 




Figure 3.6 Effects of BM derived cells on serum biochemical markers of 




















Figure 3.6 Effects of BM derived cells on serum biochemical markers of 
liver function 4 weeks after cell injection 
Advanced liver fibrosis was induced in adult female mice by the chronic 
administration of twice weekly IP CCl4. Whole BM and BMM cell experiments were 
carried out in C57Bl/6 mice, macrophage precursor cell experiments were in balb-c 
mice. 1 x 106 cells were injected via the HPV. Serum taken 4 weeks afterwards was 
analysed to determine the effect on biochemical markers of liver function.  
 (A) Serum albumin levels did not significantly change following the delivery of 1 x 
106 whole BM or macrophage precursor cells. In contrast, BMM therapy resulted in a 
significant increase in albumin levels.  
(B) Serum bilirubin levels rose just above the normal range after the application of 
whole BM cells. When testing the effects of BMM therapy, no sample in either the 
control or treatment group had a measurable serum bilirubin above the 5 µmol/L 
assay detection level (graphically represented as 5 µmol/L without error bars). Serum 
samples from the macrophage precursor cell experiment were not available for 








Tables 3.4 Effects of BM derived cells on serum biochemical markers of 
liver function 4 weeks after cell injection 
 
 






Mean  +/- SEM 
36 +/- 0.6 42.2 +/- 3.2 39.9 +/- 0.9 
Control  
N 
6 6 7 
Candidate cell  
Serum albumin 
(g/L) 
Mean  +/- SEM 
36.5 +/- 0.5 39.4 +/- 0.5 46.0 +/- 2.6 
Candidate cell 
N 
6 5 8 
P value 
 
(S = Student’s test, 
MW = Mann-Whitney 
test) 













 +/- SEM 
7.7 +/- 0.9 11.8 +/- 1.5 
N 6 6 
P value 







CHAPTER FOUR            
Cellular and molecular events 





The previous chapter describes the therapeutic changes caused by the application of 
BMMs in contrast to their specific BM precursors and unfractionated (whole) BM. I 
went on to examine the underlying cellular and molecular processes following BMM 
delivery. With regard to clinical translation, a robust approach is to have a clear 
characterisation of the donor cells to be given and also their in vivo effects based on 
experimental models. These data can then inform the rational design of clinical 
studies to test efficacy in cirrhotic patients. 
 
These studies involved analysing the phenotype of donor BMMs, tracking their 
passage in recipient liver and measuring the effects on mediators of liver fibrosis, 
inflammation and regeneration. Interestingly, it became apparent that whilst the 
changes detected in the host liver were initiated by the delivery and engraftment of a 
relatively small number of donor BMMs, this also involved a paracrine interaction 
with host cells to mediate these whole organ effects. 
 
This work was carried out in the well characterised CCl4 model of liver injury and 
fibrosis. To determine whether BMM therapy had utility in a predominantly 





Key changes occur relatively early following BMM therapy 
Following identification of the improvement in liver fibrosis and serum albumin 4 
weeks after BMM delivery, tissue from this time point was examined to determine 
the cellular and molecular changes underpinning these effects.  
 
α-SMA positive myofibroblasts are considered to be the predominant source of ECM 
synthesis during fibrogenesis. There is an increase in the number of scar producing 
myofibroblasts during chronic liver injury. Conversely, apoptosis of myofibroblasts 
is a critical early event during the resolution of fibrosis (Iredale, Benyon et al. 1998). 
Therefore, the area of α-SMA staining was measured using image analysis software. 
This did not show a statistically significant reduction in myofibroblasts 4 weeks after 
BMM delivery (figure 4.1A, B). As described, MMPs (in particular MMP-13 and 
MMP-9) are known to be key mediators of matrix degradation in the liver. Therefore 
gene expression of these enzymes was also measured at this time point. This showed 
no significant change in either MMP-13 or MMP-9 expression (figure 4.1C, D). 
 
In order to detect a pro-regenerative stimulus to the recipient liver as a potential 
explanation for the increase in serum albumin, I investigated both the hepatocyte and 
LPC compartments. Quantification of Ki67 positive hepatocytes as a marker of 
cellular proliferation (Gerlach, Sakkab et al. 1997) did not reveal a significant increase 
following BMM delivery at this 4 week time point (figure 4.2A, B). Similarly, 
quantification of PCK positive LPCs did not show any difference at this stage (figures 
4.2C, D). 
 
The transfer of male donor BMMs into female mice allows detection of donor cells by 
FISH for the Y chromosome. Interestingly, by 4 weeks, donor BMMs were not 
detected in the recipient liver (figure 4.3C). Therefore the next set of experiments was 
designed to examine the early changes occurring after BMM delivery in order to 
detect the key events responsible for the observed phenotype (figure 4.2E). 
95 
 





Figure 4.1 No difference in mediators of fibrosis detected 4 weeks after 
BMM therapy 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Photomicrographs show α-SMA staining for myofibroblasts 4 weeks after BMM 
delivery. Original magnification, x200. 
(B) Morphometric analysis demonstrates that there was not a statistically significant 
reduction in α-SMA staining in the BMM recipient group at this time point.  
(C, D) Gene expression of the fibrolytic enzymes MMP-13 and MMP-9 was not 
elevated 4 weeks after BMM therapy (compared with control recipients; n=7-8 per 
group). 
These histograms are derived from the data in table 4.1 below; all values are 




Table 4.1 No difference in mediators of fibrosis detected 4 weeks after 
BMM therapy 
 Control  BMMs 
α-SMA % 
Mean +/- SEM 








MMP-13 gene expression 
Mean +/- SEM 
8.0 +/- 1.3 9.4 +/- 2.8 
MMP-13 gene expression 
N 
7 8 
P value (Student’s t test) 0.68 
 
MMP-9 gene expression 
Mean +/- SEM 
6.3 +/- 2.2 5.9 +/- 1.5 
MMP-9 gene expression 
N 
7 8 











Figure 4.2 No difference in mediators of regeneration detected 4 weeks 





Figure 4.2 No difference in mediators of regeneration detected 4 weeks 

















Figure 4.2 No difference in mediators of regeneration detected 4 weeks 
after BMM therapy 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Photomicrographs show Ki67 staining to identify proliferating hepatocytes 4 
weeks after BMM delivery. Original magnification, x200. 
(B) Cell counting demonstrates that there was not a significant increase in the 
number of Ki67 positive hepatocytes in the BMM recipient group. 
(C) Photomicrographs show PCK staining to identify LPCs 4 weeks after BMM 
delivery. Original magnification, x200. 
(D) Cell counting demonstrates that there was not a significant increase in the 
number of PCK positive oval cells in the BMM recipient group (compared with 
control recipients; n=7-8 per group). 
These histograms are derived from the data in table 4.2 below; all values are 
expressed as a ratio of the mean of the internal control group. 
(E) Given that potentially mechanistic changes were not detected 4 weeks after BMM 
injection, subsequent experiments examined the early effects of BMM delivery. This 
schematic illustrates the experimental protocol testing the effects of 1x106 BMMs 





Table 4.2 No difference in mediators of regeneration detected 4 weeks 
after BMM therapy 
 
 Control  BMMs 
Ki67+ hepatocytes / x200 field 
Mean +/- SEM 
1.4 +/- 0.4 2.0 +/- 0.3 
Ki67+ hepatocytes / x200 field  
N 
8 7 
P value (Student’s t test) 0.21 
 
PCK+ LPCs / x200 field  
Mean +/- SEM 
3.9 +/- 0.2 3.5 +/- 0.5 
PCK+ LPCs / x200 field  
N 
7 7 









BMMs transiently engraft in the fibrotic liver 
In previous reports of successful cell therapy in experimental models (Sakaida, Terai 
et al. 2004; Nakamura, Torimura et al. 2007), the donor cells have been considered to 
have direct effects on liver remodelling and also to transdifferentiate into cell types 
that might assist liver function (e.g. hepatocyte-like cells or vascular endothelium). I 
therefore sought to track the donor BMMs in the recipient liver.  
 
Engraftment of donor BMMs was assessed using 2 independent cell tracking 
techniques. Sex mismatch bone marrow transplantation (male BM to female 
recipient) has been used as a means of tracking BM cells in the female liver (Duffield, 
Forbes et al. 2005; Russo, Alison et al. 2006). Y chromosome FISH of control wild type 
female and male liver sections confirmed that the Y chromosome probe is specific, 
not blinding to female tissue (figure 4.3A). Therefore the presence of the Y 
chromosome (detectable by FISH) indicates a donor cell in these experiments. 
Importantly, the nucleus will not always be detected in the tissue section when 
quantifying engraftment by this method. Therefore, as described in the methods 
chapter, a correction coefficient was calculated to improve the accuracy of the 
estimate of the number of engrafted cells.  
 
The second tracking technique involved delivering donor BMMs that constitutively 
express GFP (Pratt, Sharp et al. 2000). This allowed subsequent 
immunohistochemical or fluorescent detection of donor cells. 
 
The majority of identified donor BMMs detected by either method were located 
either within the hepatic scar or closely apposed to it (figure 4.3B). 1 day after the 
delivery of 1 x 106 BMMs, the mean number of engrafted donor BMMs was 6.9 per 
x200 magnification field by GFP immunostaining. Quantification of male donor 
BMMs using Y chromosome FISH revealed 6.5 donor BMMs per x200 magnification 
field at this time point. From day 1, this figure decreased to 5.3 within the first week. 
Extensive examination of sections from the 4 week time point demonstrated that 
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donor BMMs were no longer detected in recipient livers (figure 4.3C). Hepatic 
macrophages are known to turnover rapidly (Crofton, Diesselhoff-den Dulk et al. 
1978), so the longevity of donor BMMs is in keeping with expectations of host hepatic 
macrophages in this regard. The transience of donor BMM engraftment supported 
the hypothesis that the important mechanistic events resulting in the observed 









Figure 4.3 BMMs transiently engraft the fibrotic liver 
Advanced liver fibrosis was induced in adult female mice by the chronic 
administration of twice weekly IP CCl4. Donor BMMs engraft transiently in the liver.  
(A) Y chromosome FISH is specific for only detecting male cells. Original 
magnification, x320. 
(B) Syngeneic donor cells were tracked by treating wild type fibrotic CBA mice with 
GFP positive BMMs (arrowed). Original magnification x200. In addition, syngeneic 
male donor cells (arrowed) were detected within injured female C57Bl/6 liver using 
FISH for the Y chromosome. Original magnification, x320. 
(C) Quantification of donor BMM engraftment by Y chromosome FISH demonstrated 
a reduction in number during the first 7 days after BMM delivery. No donor cells 




Early reduction in myofibroblasts following BMM delivery 
The area of α-SMA staining in the BMM treatment group decreased within the first 
week (figure 4.4A) falling to 40% of control recipients 7 days after BMM therapy (P < 
.05, figure 4.4B). As described, the decrease in myofibroblasts was no longer 
statistically significant 1 month after intervention (P = .29) suggesting that the peak 
anti-fibrotic effect upon the myofibroblast population occurs relatively soon after 
BMM delivery. Double staining for TUNEL with α-SMA revealed that scar associated 
myofibroblasts underwent apoptosis during this reduction (figure 4.4C). 
 
Given the major contribution of hepatic myofibroblasts to ECM deposition during 
liver injury, this marked reduction in the amount of scar producing cells is likely to 
be responsible for a significant component of the observed anti-fibrotic phenotype. 
 
Whilst not the focus of this body of work, the increase in fibrosis following the 
delivery of whole BM is of biological and translational interest. α-SMA staining of 
BM recipients 4 weeks after cell delivery did not show a statistically significant 
increase in myofibroblasts (figure 4.5A, B). Given previous studies demonstrating a 
BM origin for hepatic myofibroblasts (Russo, Alison et al. 2006), FISH for the Y 
chromosome was performed to determine whether donor cells of BM origin had 
engrafted in the fibrotic recipient liver. No male cells were detected at this 4 week 
time point. This does not exclude the engraftment of BM cells (e.g. MSCs) that could 
differentiate into myofibroblastic cells as they may not have persisted for the 4 week 
period. In addition, the absolute number of such cells within the total of 1x106 whole 
BM cells would be low presenting a practical limitation in terms of detection. 
Alternatively, there may be early paracrine influences from BM cell populations 









Figure 4.4 BMM therapy causes a reduction in hepatic myofibroblasts 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. BMM delivery causes a reduction in the 
amount of hepatic myofibroblasts. 
(A) Photomicrographs demonstrate the reduction in α-SMA positive myofibroblasts 
7 days after BMM delivery. Original magnification, x80. 
(B) Morphometric analysis of α-SMA immunostaining revealed that myofibroblast 
numbers decreased within 7 days of BMM treatment, this effect did not persist to 4 
weeks after infusion. This histogram is derived from the data in table 4.3 below; all 
values are expressed as a ratio of the mean of the internal control group. This allows 
relative comparison of BMM effect between experiments at different time points. 
(C) Dual staining for TUNEL (green) and α-SMA (red) demonstrated the presence of 
apoptotic myofibroblasts 3 days after BMM delivery. (* P < .05 compared with 




Table 4.3 BMM therapy causes a reduction in hepatic myofibroblasts 
 
 Control  BMMs 
α-SMA % 
1 day after injection 
Mean +/- SEM 
3.3 +/- 0.6 2.7 +/- 0.5 
α-SMA % 
1 day after injection 
N 
6 6 
P value (Student’s t test) 0.41 
 
α-SMA % 
3 days after injection 
Mean +/- SEM 
1.1 +/- 0.3 0.8 +/- 0.3 
α-SMA % 
3 days after injection 
N 
5 6 
P value (Student’s t test) 0.44 
 
α-SMA % 
7 days after injection 
Mean +/- SEM 
2.7 +/- 0.5 1.1 +/- 0.3 
α-SMA % 
7 days after injection 
N 
6 5 







Figure 4.5 Unfractionated (whole) BM cell delivery does not significantly 







Figure 4.5 Unfractionated (whole) BM cell delivery does not significantly 
increase the amount of hepatic myofibroblasts 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Photomicrographs demonstrate similar amounts of α-SMA positive 
myofibroblasts 4 weeks after whole BM delivery. Original magnification, x80. 
(B) Morphometric analysis of α-SMA immunostaining revealed that there was not a 
significant increase in the amount of hepatic myofibroblasts. (n=6 per group). This 
histogram is derived from the data in table 4.4 below; all values are expressed as a 





Table 4.4 Unfractionated (whole) BM cell delivery does not significantly 









Mean  +/- SEM 0.7 +/- 0.3 1.1 +/- 0.3 
N 6 6 




Upregulation of matrix metalloproteinase expression following 
BMM therapy 
A key component of fibrosis resolution is the degradation of ECM mediated by the 
MMP family of enzymes. Therefore I examined the expression of MMPs in whole 
liver tissue during the first week after BMM delivery.  
 
Within 1 day of BMM therapy, whole liver gene expression of MMP-9 was elevated 
by 510% above control recipients (P < .05). In parallel with this was a group-wide 
trend towards increases in MMP-13 (P = .21), MMP-8 (neutrophil collagenase, P = .17) 
and MMP-12 (macrophage metalloelastase, P = .08) (figure 4.6A). Interestingly, this 
was not a universal phenomenon across the MMPs. MMP-2 has been shown to have 
pro-fibrotic actions potentially mediated by supporting HSC proliferation (Preaux, 
Mallat et al. 1999). In contrast to MMPs -8, -9 and -13, there was a non-significant 
reduction in MMP-2 expression at all measured time points in the first week 
following BMM delivery (figure 4.6A). 
 
Given the magnitude of MMP-9 upregulation, the next line of investigation was to 
determine the origin of MMP-9. Hepatic macrophages have previously been 
identified as the predominant cellular source of MMP-9 in the fibrotic liver (Knittel, 
Mehde et al. 1999). Therefore I explored the possibility of the donor BMMs being 
responsible for this increase in MMP-9 expression. As male donor BMMs were given 
to female mice, combining MMP-9 immunostaining with FISH for the Y chromosome 
allowed this hypothesis to be tested. Control male tissue confirmed that male (Y 
chromosome positive) MMP-9 producing cells were detectable (figure 4.6B). 
Interestingly, donor cells in the BMM recipients’ livers did not show co-localisation 
of these signals indicating that the donor BMMs were not expressing MMP-9 in vivo 
(figure 4.6C).  Further dual staining for MMP-9 and the macrophage marker F4/80 
demonstrated that these signals were also topographically distinct (figure 4.7A). The 
lobulated nuclei of the MMP-9 positive cells in this panel gave an indication as to 
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their identity. Staining for the neutrophil marker Ly-6G with MMP-9 showed that 
hepatic neutrophils were in fact responsible for production of this enzyme and were 
mostly located within the scar or closely associated areas (figure 4.7B i, ii). 
 
As previously described, hepatic macrophages within or closely apposed to the scar 
(SAMs) are a critical source of MMP-13. This is functionally important during the 
resolution of fibrosis on cessation of injury (Fallowfield, Mizuno et al. 2007). Serial 
section analysis of MMP-13 and F4/80 staining confirms that a subset of SAMs in 




Figure 4.6 MMP-9 expression is upregulated in BMM recipients but is not 
produced by donor macrophages  
 
Control male liver  
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Figure 4.6 MMP-9 expression is upregulated in BMM recipients but is not 
produced by donor macrophages 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Whole liver gene expression of MMP-9 was significantly elevated in BMM 
recipients within 1 day of delivery. Gene expression levels of MMPs-8, -12 and -13 
were not significantly increased. By day 3, these levels had reduced (* P < .05, ** P < 
.01 compared with control recipients per time point; n=5-6 per group). This graph is 
derived from the data in tables 4.5 below; all values are expressed as a ratio of the 
mean of the internal control group. 
(B) The Y chromosome probe (green) co-localised with MMP-9 (red) in control male 
liver indicating successful co-staining of male MMP-9 expressing cells (arrow). 
Following injection of male BMMs into female recipients however, (C) male donor 





Table 4.5 MMP-9 expression is upregulated in BMM recipients but is not 
produced by donor macrophages 
 
MMP gene expression 
Time after 
injection 
1 day  3 days  7 days 
Sample Control BMMs Control BMMs Control BMMs 
MMP-2 
Mean  















6 6 5 6 6 5 
P value 0.87 (S) 0.79 (MW) 0.59 (S) 
   
MMP-8 
Mean  
















6 6 5 6 6 5 
P value 0.17 (S) 0.15 (S) 0.06 (S) 
   
MMP-9 
Mean  















6 6  5 6  6 5 
P value <0.01 (MW)  0.17 (S)  0.22 (S) 
     
MMP-13 
Mean  















6 6  5 6  6 5 
P value 0.21 (S)  0.08 (MW)  0.6 (S) 
 
(S = Student’s test, 














Figure 4.7 Identification of the cellular sources of MMP-9 and MMP-13 in 
BMM recipients 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
(A) Dual staining for MMP-9 (red) and F4/80 (green) demonstrates that hepatic 
macrophages (arrowheads) did not express MMP-9 (arrows) in BMM recipients. 
Original magnification, x1000. 
(B i) Co-localisation (arrows) of the neutrophil marker Ly-6G (red) with MMP-9 
staining (green) indicates that hepatic neutrophils were expressing MMP-9 in BMM 
recipients. Original magnification, x320. (B ii) The x200 magnification demonstrates 
that most of these scar associated neutrophils produced MMP-9. 
(C) Immunostaining of serial liver sections demonstrates that a subset of scar 
associated F4/80 positive macrophages produced MMP-13 (arrowed). Original 




To characterise further the increased expression of MMPs following BMM delivery, 
recipient livers were immunostained for MMP-9 and MMP-13. Examination of these 
sections revealed that the cells producing these ECM degrading enzymes were 
predominantly located in or closely around the scar (figure 4.8A). Quantification of 
positively stained cells demonstrated an increase in the numbers of MMP-9 and 
MMP-13 expressing cells within 1 day of donor macrophage delivery (figure 4.8B). 
 
This early increase in hepatic MMP-9 following BMM delivery precedes the 
reduction in myofibroblasts at the 7 day time point. The contribution of upregulated 
MMP-9 levels to the reduction in myofibroblasts has been shown in vitro by the 
finding that the application of recombinant MMP-9 to cultured HSCs results in their 
apoptosis, possibly through dissolution of ECM-integrin mediated survival signals to 
HSCs (Zhou, Murphy et al. 2004). This is consistent with the observed apoptosis of 
myofibroblasts (figure 4.4C) detected in conjunction with falling numbers of 
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Figure 4.8 Increased numbers of MMP-9 and MMP-13 positive cells 
following BMM therapy 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
 (A) Immunohistochemical analysis of liver sections 1 day after BMM delivery 
revealed infiltration of MMP-13 and MMP-9 positive cells (arrowed). Original 
magnification, x320 and x200 respectively. 
(B) The numbers of MMP-13 and -9 expressing cells were significantly elevated in 
BMM recipients (* P < .05, ** P < .01, compared with control recipients per time point; 




Table 4.6 Increased numbers of MMP-9 and MMP-13 positive cells 
following BMM therapy 
 
 MMP-13+ cells  MMP-9+ cells 
Sample Control BMMs Control  BMMs 
Mean  









N 6 6 6 6 
P value 0.01 (S) 0.03 (MW) 
 
(S = Student’s test, 




Host macrophages and neutrophils are recruited to the liver by 
BMM therapy 
The increased whole liver expression of predominantly neutrophil mediated MMP-9 
and macrophage mediated MMP-13 could be due to a phenotypic switch amongst 
the resident hepatic leucocyte populations or recruitment of these cells to the liver. I 
therefore examined the absolute numbers of neutrophils and macrophages in 
recipient livers following BMM delivery. Within 1 day of BMM delivery, there was a 
marked change in the cellular composition of the fibrotic liver. F4/80 
immunostaining and quantification revealed a 44% increase in macrophage number 
(P < .05, figures 4.9A, B). The absolute increase in macrophages in BMM treated mice 
(from 53 to 76, i.e. an additional 23 per x200 field) significantly exceeds the number of 
donor BMMs (mean <7) in the same area of tissue. This suggests that the majority of 
these macrophages could be recruited to the liver as opposed to being of donor 
origin. Ly-6G immunostaining showed a 242% increase in hepatic neutrophil 
numbers (P < .01, figures 4.9A, B) at this time point.  
 
Analysis of candidate chemokines in recipient livers was undertaken in order to 
investigate the mechanism of neutrophil and macrophage recruitment. Whole liver 
extract was assayed to determine the concentration of these proteins during the first 
7 days after BMM delivery. In keeping with the early increase in neutrophil and 
macrophage numbers, samples from the 1 day time point revealed that BMM 
recipients had significantly higher levels of chemokines expressed by the donor 
BMMs (figures 3.2C, 4.10C). The macrophage chemoattractant MCP-1 (CCL2) was 
upregulated to 160% (P < .001) whilst MIP-1α (CCL3) was 137% of control (P < .05). 
The neutrophil chemoattractants KC (CXCL1) and MIP-2 (CXCL2) were also 
markedly elevated (242%, P < .001 and 842%, P < .01 respectively). Macrophages and 
neutrophils can have a number of inflammatory actions in certain contexts. Therefore 
I also measured the whole liver protein levels of anti- and pro-inflammatory 
cytokines to gauge the hepatic environment in this regard at the time of cell 
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recruitment. Importantly, IL-10 protein levels were considerably elevated to 346% in 
BMM recipients (P < .05), whilst pro-inflammatory mediators such as TNF-α and IL-6 
were unchanged (figure 4.10F). The CCl4 model involves significant liver 
inflammation following toxic injury. Consequently ALT levels are high with a 
significant degree of variability.  4 weeks after BMM therapy, serum ALT levels were 
approximately 80% of control levels. However, the standard deviation of these 
results was substantial and this was not a statistically significant reduction (figure 
4.9D). 
 
Therefore, BMM therapy in the context of ongoing liver injury switches the hepatic 
milieu towards an anti-inflammatory cytokine environment whilst recruiting host 
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Figure 4.9 Host macrophages and neutrophils are recruited to the liver 
following BMM delivery 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4.  
(A) Immunohistochemical analysis of liver specimens harvested 1 day after BMM 
delivery revealed that macrophages and neutrophils were recruited to the fibrotic 
liver. Original magnification, x200.  
(B) The extent of cell influx was greater in BMM recipients than control. Absolute 
data in table 4.7. 
(C) Whole liver protein levels of macrophage and neutrophil chemokines (MCP-1, 
MIP-1α, MIP-2 and KC) were significantly elevated within 1 day of BMM delivery. 
By day 3, these levels were returning towards baseline. This graph is derived from 
the data in table 4.7 below; all values are expressed as a ratio of the mean of the 
internal control group. This allows relative comparison of BMM effect between 
experiments at different time points. Insufficient measurements of MIP-1 α levels 
above the minimum detection level from the day 3 time point precluded analysis 
(data in collaboration with Dr Tim Gordon-Walker). 
(D) Serum ALT measured 4 weeks after BMM therapy was not significantly reduced 
compared to controls. (* P < .05, ** P < .01 compared with control recipients per time 




Tables 4.7 Host macrophages and neutrophils are recruited to the liver 







Student’s test used to analyse these data. 
  
 F4/80+ cells  Ly-6G+ cells 
Sample 









Mean +/- SEM 52.9 +/- 4.2 75.9 +/- 8.9 5.2 +/- 0.7 17.8 +/- 2.9 
P value  0.04 <0.01 
Cytokine protein levels 
Time after 
injection 
1 day  3 days  7 days 
Sample Control BMMs Control BMMs Control BMMs 
KC  
Mean  
 +/- SEM 
210.5 











KC           N 5 6 5 6 6 5 

















MCP-1     N 5 6 5 6 6 5 













MIP-1α     N 5 6 n/a n/a 6 5 
P value 0.02 n/a 0.41 
 
MIP-2 Mean  













MIP-2       N 5 6 5 6 6 5 




serum ALT (u/L) 
Whole BMMs 
serum ALT (u/L) 
Mean  
 +/- SEM 
505.7 +/- 120.7 399.2 +/- 91.7 
N 7 6 
P value 0.51 
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BMM therapy stimulates regeneration of the injured liver 
Chronic liver injury with accompanying fibrosis results in activation of the 
regenerative compartments of the liver. With advancing fibrosis, progenitor cell 
mediated regeneration becomes increasingly important in addition to hepatocyte 
proliferation. 
 
Serum albumin was increased in BMM recipients 4 weeks after cell delivery (46.0 
±2.6 g/l v 39.9 ±0.9 g/l, P = .05, figure 3.6A). Proliferating hepatocytes were identified 
based on their expression of the Ki67 antigen. There was not a statistically significant 
increase in hepatocyte proliferation after BMM therapy (P = .21, figures 4.10A, B), 
however the consistently higher average count amongst BMM recipient groups at all 
time points suggests that there may be an underlying trend towards an increase. In 
line with this, there was also a trend towards an increase in the expression of the 
hepatocyte mitogen HGF (figure 4.10D). In keeping with human cirrhosis, increased 
numbers of LPCs were present in this model. 3 days after BMM delivery, whole 
tissue mRNA levels of the LPC marker CK-19 were increased by 55% over control 
recipients (1.55 ±0.1 v 1.00 ±0.2, P= .05, figure 4.10C). By day 7, there was a 
histologically evident peri-portal expansion of PCK and Dlk positive LPCs in BMM 
recipients. The number of LPCs increased by 40% over control (P < .05, figures 4.10A, 
C). Consistent with this upregulation of LPC numbers, gene expression of the LPC 
markers EpCam and Fn14 were consistently albeit non-significantly increased at 
days 3 and 7 after BMM therapy (figure 4.10C). Donor BMMs used here express high 
levels of the LPC mitogen TWEAK relative to recipient liver (table 3.1). 3 days after 
BMM therapy, at a time when hepatic macrophage numbers were increased, whole 
liver TWEAK mRNA levels were significantly elevated to 216% of control (P < .05, 
figure 4.10E).  
 
There was no increase in the level of the cytokines IL-6 and TNF-α which are also 
associated with LPC proliferation (Bird, Lorenzini et al. 2008) (figure 4.10F). IGF-1 
mRNA levels were significantly increased 3 and 7 days after BMM delivery (P < .05 
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and .001 respectively, figure 4.10E). CSF-1 protein levels increased to 165% of control 
1 day after BMM delivery (P < .01, figure 4.10F) before decreasing over the first week. 
VEGF protein levels in contrast, increased in the BMM recipients over this period, 
reaching 127% of control at day 7 (P < .05, figure 4.10F). In addition to the 
upregulation of these reparative factors, increased TWEAK expression and the 
subsequently expanded LPC compartment are also implicated in the improved 













Figure 4.10 Improved regenerative indices following BMM therapy 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. BMM delivery activated regenerative 
pathways. 
(A) Photomicrographs show Ki67, PCK and Dlk immunostaining of liver tissue 7 
days after BMM therapy. Original magnification, x200. 
(B) The number of Ki67 positive hepatocytes did not increase to a statistically 
significantly level after BMM therapy. Graphs B-F are derived from data in table G; 
all values are expressed as a ratio of the mean of the internal control group. This 
allows relative comparison of BMM effect between experiments at different points. 
(C) Increased numbers of PCK positive LPCs were detected 7 days after BMM 
infusion. This expansion was not maintained at 4 weeks. 
(D) Gene expression of a panel of LPC markers showed a consistent increase 
following BMM therapy, CK-19 expression 3 days after BMM therapy reaching 
statistical significance. (E) Gene expression of HGF was not significantly elevated in 
BMM recipients. The liver progenitor cell mitogen TWEAK was upregulated 3 days 
after BMM delivery. IGF-1 mRNA was increased 3 and 7 days after BMM treatment. 
(F) Whole liver protein levels of IL-10 and CSF-1 were elevated 1 day after BMM 
delivery, whilst IL-6 and TNF-α were unchanged. VEGF protein levels increased 
after BMM therapy reaching significance at day 7 (data in collaboration with Dr Tim 
Gordon-Walker) (* P ≤ .05, ** P < .01 compared with control recipients per time point; 
n=5-8 per group). Insufficient measurements of IL-10 levels above the minimum 
detection level from the day 3 time point precluded analysis. 
Graphs are derived from the data in table 4.8 below; all values are expressed as a 




Tables 4.8 Improved regenerative indices following BMM therapy 
 
7 days after 
BMM injection 
Ki67+ hepatocytes 
/ x200 field 
 PCK+ LPCs 
/ x200 field 
Sample Control BMMs Control BMMs 
Mean +/- SEM 1.9 +/- 0.7 2.6 +/- 0.3 9.6 +/- 1.0 13.4 +/- 1.3 
N 6 6 6 5 






LPC marker gene expression 
Time after 
injection 
3 day  7 days 
Sample Control BMMs Control BMMs 
EpCam 
Mean +/- SEM 
6.6 +/- 1.5  8.9 +/- 1.3 7.6 +/- 1.6 12.4 +/- 4.4 
EpCam     N 5 6 6 5 
P value 0.29 (Student’s t test) 0.33 (Mann-Whitney test) 
   
CK-19 
Mean +/- SEM 
5.7 +/- 0.6  8.9 +/- 1.2 8.4 +/- 2.2 14.6 +/- 5.8 
CK-19       N 5 6 6 5 
P value 0.05 (Student’s t test) 0.31 (Student’s t test) 
     
Fn14 
Mean +/- SEM 
2.5 +/- 0.5 5.3 +/- 1.8 6.8 +/- 1.9 10.3 +/- 2.9 
Fn14         N 5 6 6 5 






Tables 4.8 Improved regenerative indices following BMM therapy 




1 day  3 day  7 days 
Sample Control  
 

























0.15 0.03 0.32 




















0.13 0.25 0.48 

























Tables 4.8 Improved regenerative indices following BMM therapy 
 
Cytokine protein expression 
Time after 
injection 
1 day  3 day  7 days 
Sample Control  
 





















0.04  n/a 0.35 





















0.06 0.39 0.49 

























0.52 0.46 0.57 

























0.85 0.23 0.04 
































Macrophage viability is required for therapeutic effect 
I examined the effect of dead BMMs in this model in order to test whether 
macrophage viability and in turn the capacity for hepatic engraftment and 
subsequent biological actions (e.g. expression of mediators such as IL-10, TWEAK 
and the chemokines listed in figure 3.2C) was required to generate the therapeutic 
phenotype. This was achieved by sonicating the same dose of cells (1 x 106) such that 
no intact BMMs remained. Injection of this macrophage debris into the HPV did not 





Figure 4.11 Dead BMMs do not recapitulate the phenotype resulting from 




Figure 4.11 Dead BMMs do not recapitulate the phenotype of viable 
BMMs  
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. 
 (A) The injection of 1 x 106 sonicated BMMs into the HPV did not improve liver 
fibrosis. Photomicrographs show PSR staining for hepatic collagens 4 weeks after 
dead BMMs were delivered to syngeneic fibrotic mice (right sided column). Age and 
strain-matched mice from the same cohort received an equal volume of control 
medium (left column). Original magnification, x80. 
(B) Morphometric analysis demonstrated a non-significant trend (P = .08) towards an 
increased amount of fibrosis following the application of dead BMMs. This 
histogram is derived from the data in table 4.9 below; all values are expressed as a 
ratio of the mean of the internal control group. 
(C) Serum albumin levels were not changed by the delivery of non-viable BMMs 
(n=6-7 per group). 
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Table 4.9 Dead BMMs do not recapitulate the phenotype of viable BMMs 
 





Mean  +/- SEM 
4.9 +/- 0.5 6.2 +/- 0.5 
PSR %     N 6 7 
P value 





Mean  +/- SEM 
36+/- 0.6 36.9 +/- 0.5 
serum albumin 
(g/L)         N 
6 7 
P value 












BMMs do not improve fibrosis or regeneration in the cholestatic 
1% DDC diet model 
An important categorisation of the common aetiologies of human cirrhosis is that 
some disease processes predominantly involved parenchymal (hepatocyte) damage 
such as viral hepatitis and alcohol induced injury whilst some are cholestatic such as 
PSC and primary biliary cirrhosis (PBC). Though less prevalent, these cholangitic 
diseases are significantly different in terms of injury pattern and therefore the precise 
fibrotic and regenerative pathways involved. In order to determine the effects of 
BMM therapy in a cholestatic model, I delivered 1 x 106 donor BMMs 3 weeks into a 5 
week 1% DDC diet protocol. The DDC diet causes cholangiopathy with biliary 
fibrosis and an accompanying progenitor cell response (Fickert, Stoger et al. 2007; 
Boulter, Govaere et al. 2012). The figure below (figure 4.11) illustrates the 
experimental time course. 
 





There were no differences detected in PSR staining, PCK positive progenitor cell 
numbers or serum albumin following BMM delivery (figure 4.12). Previous work in 
our group (personal communication with Dr Luke Boulter) had shown that extended 
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periods on this diet led to a reduction in weight with an increased risk of mortality. 
Therefore in line with guidance from the Home Office veterinary surgeons, the 
protocol was designed in the light of this to prevent a high rate of death before the 
intended end of the experiment. It is possible that injecting BMMs after 3 weeks of 
injury, with a further 2 weeks before harvesting the mice, may not have been the 
optimal timeframe to detect any changes.  
 
Another plausible explanation as to why BMM therapy may be of limited value in 
cholangiopathy relates to structural aspects of this disease model. Digital 
reconstruction of the cellular relationships in this model has shown that LPCs are 
surrounded by a dense layer of myofibroblasts and collagen I effectively limiting 
macrophage access and therefore influence. This has important implications upon 
the direction of LPC fate specification. The spatial relationships in a more hepatocytic 
model (the CDE diet) demonstrate a greater number of macrophages with fewer 
myofibroblasts and collagen I around the LPC niche (Boulter, Govaere et al. 2012). 
Thus it is conceivable that macrophage based therapy may be of limited efficacy in 









Figure 4.13 BMMs did not improve fibrosis or regeneration in the DDC 
model  
The injection of 1 x 106 syngeneic BMMs into the HPV during the DDC diet injury 
model in S129 S2 mice did not lead to apparent improvements in disease phenotype. 
(A)  Photomicrographs show PSR staining for hepatic collagens 2 weeks after BMMs 
were delivered to syngeneic fibrotic mice (right sided image). Age and strain-
matched mice from the same cohort received an equal volume of control medium 
(left image). Original magnification, x200. 
(B) Morphometric analysis did not show any difference in liver fibrosis.  
(C) Photomicrographs show PCK immunostaining of LPCs (arrowed) following 
BMM delivery. Original magnification, x200. 
(D) Quantification of LPC number did not show any difference 2 weeks after BMM 
delivery. 
(E) Serum albumin levels were not changed by the delivery of BMMs in the DDC 
model (n=6-9 per group). 
Histograms are derived from the data in table 4.10 ; all values are expressed as a ratio 


























Sample Control BMMs 
PSR % 
Mean +/- SEM 





(Student’s t test) 
0.48 
 
PCK+ LPCs/ x200 field 
Mean +/- SEM 
2.7 +/- 0.2 2.6 +/- 0.1 




(Student’s t test) 
0.52 
 
serum albumin (g/L) 
Mean +/- SEM 
46.2 +/- 0.7 47.5 +/- 1.0 









From a translational perspective, the deleterious effect of unfractionated (whole) BM 
on liver fibrosis is particularly noteworthy. This could be due to components of the 
BM such as MSCs that have pro-fibrogenic actions in specific circumstances (Russo, 
Alison et al. 2006; di Bonzo, Ferrero et al. 2008). Interestingly, exogenous CSF-1R 
positive macrophage precursors did not significantly improve liver fibrosis. This 
population contains Gr-1hi (Ly-6Chi) monocytes (Sasmono, Ehrnsperger et al. 2007) 
that have pro-fibrogenic actions during liver injury (Karlmark, Weiskirchen et al. 
2009). Therefore this mixed cell population might have competing effects on net 
fibrosis. 
 
Following culture in CSF-1 conditioned medium, CSF-1R positive macrophage 
precursors within BM differentiate into macrophages (Sasmono, Ehrnsperger et al. 
2007). The BMMs used here were cultured in non-adherent conditions and possessed 
neither the typical M1 nor M2 profiles. They expressed a number of factors with 
effects on cell recruitment as well as inflammation and repair. Though donor BMM 
engraftment was transient, their effects persisted and were amplified by paracrine 
signalling to host cell populations. The net effect on the injured liver was a reduction 
in fibrosis and improvement in regeneration beyond the lifespan of the donor cells.  
 
BMM therapy caused the recruitment of MMP producing host cells into the hepatic 
scar. MCP-1 and MIP-1α are members of the CC chemokine subfamily that bind to 
the CCR2 and CCR1/5 receptors of monocytes respectively. These interactions 
contribute to the navigation of monocytes into target tissues during their maturation 
into macrophages (Mantovani, Sica et al. 2004). The delivery of MCP-1 and MIP-1α 
expressing BMMs to injured mice caused upregulation of hepatic MCP-1 and MIP-1α 
and the recruitment of endogenous macrophages. These increased numbers of SAMs 
expressed MMP-13 which has proteolytic actions on fibrillar collagens and gelatin, as 
well as activating other MMPs (including MMP-9) (Fallowfield, Mizuno et al. 2007). 
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Donor BMMs also strongly expressed MIP-1α and MIP-2. These CXC chemokines 
recruit neutrophils through the surface receptor CXCR2 (Mantovani, Sica et al. 2004).  
Within 1 day of BMM delivery, there was increased hepatic production of the 
neutrophil chemoattractants MIP-1α, MIP-2 and KC with subsequently increased 
hepatic neutrophil numbers. This is in keeping with the role of macrophage 
mediated neutrophil recruitment in fibrosis resolution following cessation of injury 
(Harty, Papa et al. 2008). During ongoing hepatic damage in the experiments 
described in this results chapter, BMM therapy induced neutrophil recruitment. Host 
neutrophils produced MMP-9 in this model. During the recovery phase after liver 
injury, endogenous BM derived neutrophils have been shown to home to the hepatic 
scar and produce MMP-9 (Higashiyama, Inagaki et al. 2007). Separately, supra-
physiological MMP-9 over-expression reduces myofibroblast number and 
fibrogenesis during experimental liver injury (Roderfeld, Weiskirchen et al. 2006). 
This suggests that BMM therapy may recapitulate certain features of the resolution 
process despite ongoing injury. The concurrent trend of increased MMP-12 
(macrophage metalloelastase) and MMP-8 (neutrophil collagenase) expression 
reinforces a fibrolytic role for recruited macrophages and neutrophils.  
 
In addition to MMPs, both IGF-1 (Sobrevals, Rodriguez et al. 2010) and IL-10 
(Thompson, Maltby et al. 1998; Huang, Shi et al. 2006) have been shown to reduce 
myofibroblast number and fibrosis. The delivery of exogenous recombinant CSF-1 
limits scar formation in murine models of myocardial infarction (Morimoto, 
Takahashi et al. 2007). The magnitude of hepatic IL-10 protein upregulation was 
considerable (346%) and may modify the behaviour of both resident and incoming 
cells as well as limiting the degree of injury. This suggests that the chemokine 
mediated recruitment of host effector cells to the injured liver, critically at a time 
when the prevailing hepatic cytokine environment is anti-inflammatory, could 
represent a novel and realistic mechanism for the therapeutic actions of 




The improved liver function following BMM therapy is multifactorial in origin. 
Elevated levels of cytokines such as CSF-1 (Menke, Iwata et al. 2009), VEGF 
(Nakamura, Torimura et al. 2007) and IGF-1 (Sobrevals, Rodriguez et al. 2010) have 
individually been shown to have powerful reparative properties. All of these factors 
were significantly upregulated following BMM delivery. Though statistically 
significant hepatocyte proliferation was not detected, there was a consistent trend at 
each time point. Ki67 is a marker of cellular proliferation; Ki67 positive hepatocyte 
number has been shown to correlate with restoration of liver mass after partial 
hepatectomy. (Zou, Bao et al. 2012) Whilst this antigen is present throughout the 
active phases of the cell cycle, quantification of mitotic hepatocytes may have 
provided more specific information regarding hepatocyte mediated regeneration 
following BMM therapy. (Marshall, Rushbrook et al. 2005) It is plausible that the 
improvement in hepatic milieu in addition to trophic signalling (e.g. by HGF) 
contribute to this regenerative compartment. BMM induced activation of the LPC 
compartment is compatible with the clinical observation that BM infusion transiently 
stimulated LPCs and improved serum albumin in a series of cirrhotic patients (Kim, 
Park et al. 2010). Given the close spatial relationship between LPCs and endogenous 
macrophages in vivo during disease  (Lorenzini, Bird et al. 2010), it was predicted 
that BMM delivered signals could support LPC activation. Exogenous TWEAK 
delivery results in LPC activation (Tirnitz-Parker, Viebahn et al. 2010) which 
parallels the observed macrophage mediated delivery of this mitogen to the site of 
action followed by LPC proliferation. Intriguingly, BMMs even activate LPCs in 
healthy, normal mice. The functional effects of the BMM – TWEAK axis in the 
uninjured liver have since been explored providing a clear role for TWEAK acting 
via the Fn14 receptor to stimulate LPCs resulting in proliferation, liver growth and 
supra-physiological serum albumin levels.(Bird, Lu et al. 2013). In the context of liver 
disease, hepatic scar degradation itself supports LPC activation (Kallis, Robson et al. 
2011). Therefore LPC proliferation is also indirectly enhanced by the macrophage 
mediated hepatic scar reduction. This highlights the multiple, overlapping effector 




The donor BMMs used here expressed high levels of TWEAK and recruited 
additional host macrophages to the injured liver. This supports the paradigm of 
donor cell derived paracrine signals having downstream actions on host cell 
populations. This could permit a numerically small number of injected (and even 




CHAPTER FIVE                   






The routes of administration of cells in human studies have included peripheral 
veins, the hepatic portal vein (HPV) and hepatic artery (HA). The most concerning 
report from the literature to date relates to complications following use of the hepatic 
artery (Mohamadnejad, Namiri et al. 2007). The safety, acceptability and costs of 
peripheral cell infusions are considerably more favourable than with the HPV or HA 
route. However, determining the efficacy of different routes of cell delivery is crucial 
in addition to assessing the associated risks. 
 
Chapters 3 and 4 report results following the HPV delivery of BM derived cells. In 
this chapter, I compare the outcomes from HPV and tail vein BMM administration. 
This was further examined by delivering a greater number of BMMs repeatedly by 
the peripheral route. The fate of donor BMMs was studied by in vivo tracking 
experiments using a transgenic GFP reporter, which provided insights into the 




A single dose of BMMs delivered via the tail vein does not produce 
therapeutic effect 
In contrast to the injection of 1 x 106 BMMs into the HPV having therapeutic effect 
(figures 3.4, 3.5 and 3.6), 1 x 106 BMMs injected into the tail vein did not improve the 
measured parameters (figure 5.2A, B and C). The schematic below (figure 5.1) 
illustrates the time course of his experiment. 
 
Figure 5.1 Schematic of CCl4 experimental protocol testing alternative 












Figure 5.2 Tail vein administered BMMs do not have therapeutic effect 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. These mice received 1 x 106 syngeneic BMMs 
or an equal volume of control medium injected by the tail vein (TV).  
(A) Morphometric analysis of PSR staining was performed to detect hepatic collagen 
4 weeks after BMMs were delivered to syngeneic fibrotic mice by the TV. There was 
no significant reduction in liver fibrosis. This histogram is derived from the data in 
table 5.1 below; all values are expressed as a ratio of the mean of the internal control 
group. This allows relative comparison of BMM effect between experiments at 
different time points. 
(B) Serum albumin levels were also unchanged following BMM delivery via the TV 





















Sample Control BMMs 
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Mean  +/- SEM 
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Repeated peripheral vein administration of BMMs does not 
recapitulate the effect of the intraportal route 
Given the lack of improvement in liver fibrosis or serum albumin following the 
single injection of 1 x 106 BMMs via the tail vein, I next tested the effects of 5 x 106 
BMMs delivered on 4 occasions at weekly intervals. 
The schematic below (figure 5.3) illustrates the time course.  
 
Figure 5.3 Schematic of CCl4 experimental protocol testing repeated 
delivery of BMMs via the tail vein 
 
The application of 5 x 106 BMMs four times over the last month of CCl4 did not 
change the amount of fibrosis, number of LPCs or serum albumin (figure 5.4). 
Therefore, further experiments were undertaken to investigate the anatomical 















Figure 5.4 Repeated applications of BMMs via the tail vein do not have 
therapeutic effect 
Advanced liver fibrosis was induced in adult female C57Bl/6 mice by the chronic 
administration of twice weekly IP CCl4. The injection of four doses of 5 x 106 
syngeneic BMMs at 1 week intervals into the TV did not lead to apparent 
improvements in disease phenotype. 
(A)  Photomicrographs show PSR staining for hepatic collagens after BMMs were 
delivered to syngeneic fibrotic mice (right sided image). Age and strain-matched 
mice from the same cohort received an equal volume of control medium (left image). 
Original magnification, x200. 
(B) Morphometric analysis did not show any difference in liver fibrosis.  
(C) Serum albumin levels were not changed by the repeated peripheral 
administration of BMMs. 
(D) Photomicrographs show PCK immunostaining of LPCs. Original magnification, 
x200. 
(E) Quantification of LPC number did not show any difference following repeated 
BMM delivery via the tail vein (n=8-11 per group). 
These histograms are derived from the data in table 5.2 below; all values are 
expressed as a ratio of the mean of the internal control group. This allows relative 
























Sample Control BMMs 
PSR % 
Mean +/- SEM 





(Student’s t test) 
0.75 
 
PCK+ LPCs/ x200 
field 
Mean +/- SEM 
9.7 +/- 0.9 9.7 +/- 0.9  





(Student’s t test) 
0.98 
 
serum albumin (g/L) 
Mean +/- SEM 
39.5 +/- 0.9 39.2 +/- 0.6  








Constitutive GFP expression does not affect the biology of donor 
BMMs 
Differentiated donor BMMs that constitutively express GFP (Pratt, Sharp et al. 2000) 
were used to allow in vivo tracking of these cells as they pass through the recipient 
circulation and organs. Firstly, experiments were performed to confirm that the 
reporter did not compromise the phenotype of these cells in terms of the therapeutic 
effects on liver fibrosis and albumin. As previously, the area of fibrosis significantly 
decreased whilst the serum albumin level was higher in the treatment group (43.3 




Figure 5.5 GFP positive BMMs delivered via the HPV improve liver 





Figure 5.5 GFP positive BMMs delivered via the HPV improve liver 
fibrosis and serum albumin 
Advanced liver fibrosis was induced in adult female wild type CBA mice by the 
chronic administration of twice weekly IP CCl4. BMMs were cultured from the BM of 
transgenic constitutively GFP expressing mice on a CBA background. BMMs were 
cultured as described in Chapter 2, fluorescence based selection was therefore not 
required. 5 x 106 GFP positive BMMs were injected into the HPV of wild type CBA 
mice 6 weeks into a 10 week CCl4 injury protocol.  
(A) Photomicrographs show PSR staining for hepatic collagens after BMMs were 
delivered to syngeneic fibrotic mice (right sided image). Age and strain-matched 
mice from the same cohort received an equal volume of control medium (left image). 
Original magnification, x200. 
(B) Morphometric analysis shows a reduction in liver fibrosis. This histogram is 
derived from the data in table 5.3 below; all values are expressed as a ratio of the 
mean of the internal control group. This allows relative comparison of BMM effect 
between experiments at different time points. 
(C) Serum albumin levels increased following administration of GFP positive BMMs. 




Table 5.3 GFP positive BMMs delivered via the HPV improve liver 
fibrosis and serum albumin 
 
Sample Control  BMMs 
PSR % 
Mean  +/- SEM 





(Student’s t test) 
0.04 
   
albumin g/L 
Mean  +/- SEM 
40.4 +/- 1.0 43.3 +/- 0.6 












Peripheral vein BMM delivery affects cell destination and hepatic 
engraftment 
To determine why the tail vein route of BMM administration did not cause the 
improvements seen after the HPV delivery of the same cells, a series of early time 
course experiments were conducted in collaboration with Dr Caroline Pope using 
BMMs expressing the stable GFP reporter (Pratt, Sharp et al. 2000). 1 x 106 GFP 
positive BMMs were delivered via the HPV or tail vein. BMM recipients were 
harvested 10 minutes and 1, 6, 12 and 24 hours after BMM delivery. In particular, the 
liver, spleen, kidneys and lungs were examined for the presence of GFP positive 
BMMs by immunohistochemistry which was then quantified (figure 5.6). 
 
Shortly after injection of BMMs via the tail vein, these cells had predominantly 
accumulated in the lungs (figure 5.6B). In contrast, few BMMs injected via the HPV 
were detectable in the lungs at this time point (figure 5.6B). The peak rate of hepatic 
engraftment was detected 6 hours after BMM delivery by the HPV (figure 5.6A). 
Interestingly, between the first hour and 1 day time points there was evidence of 
BMM migration from the vessel wall (figure 5.7C) into the parenchyma and towards 
the scar (figure 5.7D). The cells also seemed to change morphology, appearing more 
compressed (in 2 dimensions) during ingress into the solid organ. The TV delivered 
BMMs achieved less than 30% of the hepatic engraftment of HPV injected cells 
(figure 5.6A). The number of BMMs in the spleen was similar in both groups (figure 









Figure 5.6 In vivo tracking of donor BMMs during the first 24 hours after 
injection 
Advanced liver fibrosis was induced in adult female wild type CBA mice by the 
chronic administration of twice weekly IP CCl4. 1 x 106 GFP positive BMMs were 
injected into wild type fibrotic CBA recipients. Mice were then harvested at time 
points over the first day. This allowed immunohistochemical detection of the donor 
BMMs and their quantification in the (A) liver, (B) lungs and (C) spleen. This is 
graphically represented to demonstrate the kinetics of donor BMM in the host. Data 









Figure 5.7 Visualisation of donor BMMs in recipient tissue 
Donor GFP positive BMMs were injected into wild type fibrotic CBA mice. Sections 
of liver, lung, spleen and kidney were immunostained for GFP which was visualised 
fluorescently. 
(A) Tracked BMMs were detected in lung from 10 minutes after infusion by the tail 
vein (TV). 
(B) Few cells were detected in the lungs 6 hours after HPV delivery. 
(C) Hepatic BMMs (arrows) were noted to be near the vessel wall within an hour of 
HPV delivery. 
By 24 hours (D), HPV delivered BMMs (arrows) appeared to have ingressed into the 
liver parenchyma. 
(E) BMMs were only detected infrequently in the kidney; this is a representative 
image 12 hours after the HPV injection of BMMs. 
(F) The numbers of BMMs in the spleen were fairly constant, this image is from 12 
hours after the TV administration of BMMs. Data in collaboration with Dr Caroline 




These data confirm that the TV delivery of BMMs resulted in markedly fewer donor 
cells engrafting in the liver. Therefore the lack of response to cells by this route may 
in part be dose related. However, the experiments outlined in figures 5.3 and 5.4 
used significantly greater numbers of BMMs delivered repeatedly to address this 
issue. A limiting factor could potentially be insufficient numbers of donor BMMs in 
the liver to trigger the threshold required to initiate the cascade of events resulting in 
the amplification of effects already discussed in chapter 4. Another issue could be 
that the TV route requires BMMs to pass through the pulmonary vasculature at least 
once before having the opportunity to engraft in the injured liver. Some of these cells 
may remain in the lungs for a number of hours before transiting to the liver. This 
could result in phenotypic change of these donor BMMs by the host pulmonary 
micro-environment. It is plausible that this could affect the subsequent behaviour of 
donor BMMs in the liver and introduce functional heterogeneity to this cell 
population. 
 
Route related differences on the effects of cell therapy have since been reported by 
Wang and colleagues (Wang, Lian et al. 2012). Though MSCs and macrophages have 
different biological actions, the donor cell dose and route to the liver could also 
explain why they found that MSCs had similarly therapeutic effects on mouse liver 






CHAPTER SIX      





Key findings and their integration with the literature 
Liver fibrosis and regeneration are intrinsically linked processes which are both in 
part directed by host macrophages. The effects of HPV delivered exogenous BMMs 
on these pathways are summarised in figure 6.1. Following hepatic engraftment of 
donor BMMs, there is upregulation of chemotactic mediators and increased scar 
cellularity particularly comprising host macrophages and neutrophils. This is 
accompanied by a significant early increase in hepatic levels of the anti-inflammatory 
mediator IL-10. Host hepatic macrophages and neutrophils express scar degrading 
MMPs. There is a subsequent reduction in fibrogenic myofibroblasts and liver 
scarring. Donor BMMs also expressed the LPC mitogen TWEAK and caused 
expansion of the stem cell compartment with elevated serum albumin levels.  
 
The potentially harmful effects of unfractionated (whole) BM represent an important 
caveat for human studies. Following publication of these findings (Thomas, Pope et 
al. 2011), a Japanese group have reported data with a number of similarities 
(Iwamoto, Terai et al. 2013). Though the culture of donor BM cells was by a different 
protocol, a significant proportion of infused (and engrafted) cells were F4/80 positive 
macrophages. Cell injection caused upregulation of hepatic MMP-9 with a reduction 
in fibrosis. A fraction of the infused cells was considered to contain MSCs; consistent 
with this, vimentin positive cells of donor origin were identified. This indicates the 
possibility of supplying cells with the potential to have myofibroblast-like actions, 
highlighting the benefits of using a defined and committed cell population. 
 
Subsequently published data from our group has shown that during fibrosis 
regression following the cessation of CCl4 injury, circulating macrophages are 
recruited to the liver and switch phenotype to upregulate MMP expression and exert 
anti-fibrotic actions (Ramachandran, Pellicoro et al. 2012). Though a distinct process 
from this study of ex vivo cultured cells delivered as therapy in the context of 




In addition to the literature concerning cell therapy for liver disease, these findings 
can also be viewed in the context of macrophage cell therapy in diabetes and renal 
and pulmonary disease models. The ability of macrophages to home to sites of 
inflammation has been utilised to target these cells to the injured organ in question. 
In a rat model of nephrotoxic nephritis, macrophages transfected with adenovirus 
expressing IL-4 reduced albuminuria (Kluth, Ainslie et al. 2001), whilst transfection 
with adenovirus expressing IL-10 also produced anti-inflammatory effects and 
improved albuminuria (Wilson, Stewart et al. 2002). Distinct from the specific over-
expression of a reparative cytokine, the delivery of wild type macrophages in a 
transgenic murine model of pulmonary alveolar proteinosis (GM-CSF receptor β 
subunit -/-) corrects the host deficiency thereby treating the lung disease (Suzuki, 
Arumugam et al. 2014). 
 
In contrast to direct genetic modification of or by macrophages, ex vivo direction of 
macrophages towards the stereotypical M2 phenotype prior to injection has been 
successful in preventing type 1 diabetes in NOD mice (Parsa, Andresen et al. 2012). 
Macrophages influenced towards the M2 phenotype also ameliorated renal injury in 
severe combined immunodeficient (SCID) mice with adriamycin nephropathy 
(Wang, Wang et al. 2007). Though a useful construct, the M1 M2 paradigm is 
considered a simplification that does not reflect the biological spectrum of 
macrophage phenotypes (Mosser and Edwards 2008). The BMMs given as therapy in 
this thesis were not polarised ex vivo to express the typical M1 or M2 profiles. 
Similarly, unstimulated macrophages have also been shown to have anti-fibrotic 
effects in a murine model of renal fibrosis caused by cyclophosphamide exposure 




Figure 6.1 The effects of HPV delivered BMMs on key processes in liver 




Figure 6.1 The effects of HPV delivered BMMs on key processes in liver 
fibrosis and regeneration during chronic liver injury 
 
This figure illustrates the consequences of donor BMM injection via the HPV on 
mediators of liver fibrosis and regeneration in the context of ongoing liver injury. 
There is an increase in host macrophages and neutrophils within the hepatic scar. 
These cells produce scar degrading MMPs. The amount of hepatic myofibroblasts 
decreases and there is a reduction in liver fibrosis. Concurrently, there is increased 
expression of regenerative mediators such as TWEAK and activation of the 
progenitor cell compartment of the liver with subsequent elevated serum albumin 
levels. Thus BMM delivery causes structural and functional improvements in this 




Route and timing of BMM therapy 
Selection of the optimal route of cell delivery is a critical issue for translation. 
Peripheral injection has the significant advantages of safety, technical ease, reduced 
costs and greater acceptability to patients. Radiologically guided techniques to 
deliver cells into the HPV and HA are well established and have been used in 
preliminary human studies (e.g. (Lyra, Soares et al. 2010), (Nikeghbalian, Pournasr et 
al. 2011)). There are several positive reports of cell therapy delivered via peripheral 
veins (e.g. (Kim, Park et al. 2010), (Terai, Ishikawa et al. 2006) however the precise 
cell type used would likely affect its relative success. Despite increasing the BMM cell 
dose and delivering multiple injections, peripherally delivered BMMs did not 
demonstrate beneficial effects in the setting of murine CCl4 induced liver fibrosis. In 
contrast, peripherally delivered BMMs do cause LPC activation in uninjured mice 
(Bird, Lu et al. 2013). This difference in effect could relate to circulatory changes 
associated with advanced fibrosis or the inflammatory milieu in chronic injury. The 
results in Chapter 5 demonstrate that significantly fewer cells engrafted within the 
host liver following peripheral as opposed to HPV delivery during liver injury. 
Furthermore, these tracking studies also showed that peripherally administered 
BMMs passed through the pulmonary circulation and so may undergo phenotypic 
changes that could affect their subsequent actions in the liver. 
 
Further work in this area could examine the specific phenotype of BMMs in these 
different contexts. Delivering GFP positive BMMs to wild type fibrotic mice either 
peripherally or via the HPV would permit fluorescence based BMM extraction from 
selected organs at specific time points. The retrieved BMMs could then be 
characterised to determine phenotypic changes that may have arisen as a 
consequence of their passage in the host. 
 
Given the significantly longer duration of human chronic liver disease, it is possible 
that small changes from each treatment could accumulate over time to yield 
meaningful clinical improvement. Clinical studies of in vivo tracking of donor cells 
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(Couto, Goldenberg et al. 2011) will improve our understanding of the kinetics of cell 
traffic. Technological improvements in vascular interventional radiology may also 
allow safer and more convenient access to the hepatic vessels.  
 
The timing and need for multiple treatments would depend on the aetiology of 
cirrhosis and precise clinical circumstances. In the setting of ongoing liver damage 
without complete control of inflammation (e.g. non-alcoholic steatohepatitis, 
autoimmune hepatitis) with a clinical course usually measured in years, maintaining 
significant improvements in disease would likely need repeated intervention. 
Resolution of the chronic hepatic insult (e.g. successful antiviral therapy, abstinence 
from alcohol) can lead to sufficient regression to allow recompensation of cirrhosis 
and obviate the need for transplantation in some patients. An application for shorter 
term cell therapy might be to consolidate this process and increase the proportion of 
patients achieving this outcome. 
 
Patient selection and disease models 
The majority of chronic liver disease worldwide is the result of predominantly 
parenchymal injury. Current therapies for the less common cholestatic liver diseases, 
PBC and PSC, are of limited effectiveness. The DDC model of murine biliary injury 
was used to test whether BMM therapy could confer benefit in this setting. The 
positive effects of BMMs in the CCl4 model of hepatitic type liver disease but not in 
the DDC model of biliary disease is compatible with subsequently published work 
from our group (Boulter, Govaere et al. 2012). This showed that infiltrating 
macrophages have restricted access to key non-parenchymal cells in biliary disease. 
Furthermore, macrophages were identified as critical determinants of LPC 
differentiation down the hepatocyte lineage in the setting of predominantly hepatitic 
injury. The negative results of BMM therapy in this cholestatic model are potentially 
attributable to a number of factors in addition to this mechanistic explanation. As 
previously described, experience in our group found the DDC model to be highly 
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toxic with a substantial mortality at higher doses. Such considerations led to 
restrictions on experimental design with pragmatic decisions made regarding the 
duration of injury and timing of therapy.  
 
Future work to interrogate this further would include delivering BMMs at different 
time points during biliary injury and also using alternative cholangiopathic models 
such as bile duct ligation or alpha-naphthylisothiocyanate (ANIT). The possibility 
that BMM therapy may not be of utility in biliary disease has important implications 
for patient selection in clinical studies. It is plausible that patients with cirrhosis due 
to viral hepatitis and alcohol excess will be more likely to benefit than cirrhotic 
patients with chronic cholestatic disease. 
 
Other limitations of this work 
The CCl4 model exhibits a high degree of reversibility upon cessation of injury in the 
experimental setting. This has made it a useful and popular tool to examine the 
mechanisms underlying fibrolysis and the experimental potential of candidate 
therapies. Fibrosis resolution is seen in clinical practice, a notable example being the 
successful treatment of HCV followed by histological regression of cirrhosis 
(Poynard, McHutchison et al. 2002). An important difference however, is that human 
disease has a significantly longer timeframe than experimental models. Mature 
fibrosis is characterised by a less cellular scar with increased elastin (Pellicoro, Aucott 
et al. 2012) and is less amenable to resolution (Issa, Zhou et al. 2004). Also of 
importance is the fact that a significant proportion of patients with cirrhosis are aged. 
Cellular senescence has consequences on regenerative pathways (Marshall, 
Rushbrook et al. 2005) and also fibrogenesis and its regression (Casado, Quereda et 
al. 2013). The physiology underlying this is not well characterised at present however 




Further work would therefore test the effects of BMM therapy in models of 
significantly advanced fibrosis and also in aged mice. The magnitude of effect seen in 
the rodent models may not ultimately be reflected in humans. Even so, clinically 
meaningful improvement e.g. from decompensated to compensated cirrhosis, may 
be achievable with relatively limited structural change. 
 
Donor BMMs have multiple actions, some direct and others mediated indirectly 
through the recruitment of host effector cells. The multiple, overlapping pathways 
demonstrate the multi-faceted effects of cell therapy. This contrasts with studies of 
single molecules or genes where the effects of the single pathway can be shown. 
With regard to clinical translation, the use of a readily available, differentiated, 
single cell type increases the predictability of effect. These findings will inform the 
rational design of clinical studies to determine the efficacy of autologous 
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Appendix One          




Since the first description of experimental liver fibrosis induced by CCl4 in 1926, this 
model has been particularly attractive due to its relative consistency, rapidity and 
similarity to human disease. (Sellers, Lucas et al. 1948) The repeated administration 
of CCl4 results in probably the most used and best characterised experimental model 
of rodent liver fibrosis.(Constandinou, Henderson et al. 2005) In addition to the 
substantial literature, there was considerable experience of its use in our research 
group and animal facility. To confirm its safe administration and reliability, I 
undertook preliminary work in collaboration with Dr Caroline Pope who was 
examining rat liver fibrosis. Twice weekly IP injection of CCl4 was performed safely 
in adult female rats. 
 
Rats were harvested at 8 (n=4), 10 (n=3) and 12 (n=4) weeks of injury. PSR staining of 
liver sections was compared to control subjects (n=8) that had not received CCl4. 
Appendix One figure 1 demonstrates that repeated CCl4 injections caused liver 
fibrosis. The degree of variation can partly be explained by the small size of these 
preliminary groups. Subsequent work focused on murine models in line with the 
majority of the recent literature on experimental liver fibrosis and regeneration. This 
work informed subsequent experiments; larger groups were used and intergroup 
comparison of treatment effect was only made in the context of controls from the 









Appendix 1 figure 1 CCl4 causes liver fibrosis in rats 
(A) PSR staining was performed to detect hepatic collagen after I.P. CCl4 
administration to adult female rats. Representative images show the increased 
staining following repeated CCl4 delivery. Original magnification, x200. 
(B) Morphometric analysis shows the relationship between duration of injury and 




Appendix 1 table 1 CCl4 causes liver fibrosis in rats 
 
Sample Control  
(PSR %) 
8 weeks CCl4  
(PSR %) 
10 weeks CCl4  
(PSR %) 
12 weeks CCl4  
(PSR %) 
Mean  
 +/- SEM 
0.69 +/- 
0.12 
1.82 +/- 0.50 0.96 +/- 0.2 2.56 +/- 0.12 









Macrophage Therapy for Murine Liver Fibrosis Recruits
Host Effector Cells Improving Fibrosis, Regeneration,
and Function
James A. Thomas,1,2 Caroline Pope,1,2 Davina Wojtacha,1,2 Andrew J. Robson,1,2 Timothy T. Gordon-Walker,1
Stephen Hartland,1 Prakash Ramachandran,1,2 Marielle Van Deemter,1 David A. Hume,3 John P. Iredale,1
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Clinical studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the
mechanisms of benefit remain undefined. Cells of the monocyte-macrophage lineage have
key roles in the development and resolution of liver fibrosis. Therefore, we tested the ther-
apeutic effects of these cells on murine liver fibrosis. Advanced liver fibrosis was induced
in female mice by chronic administration of carbon tetrachloride. Unmanipulated, synge-
neic macrophages, their specific BM precursors, or unfractionated BM cells were delivered
during liver injury. Mediators of inflammation, fibrosis, and regeneration were measured.
Donor cells were tracked by sex-mismatch and green fluorescent protein expression. BM-
derived macrophage (BMM) delivery resulted in early chemokine up-regulation with
hepatic recruitment of endogenous macrophages and neutrophils. These cells delivered
matrix metalloproteinases-13 and -9, respectively, into the hepatic scar. The effector cell
infiltrate was accompanied by increased levels of the antiinflammatory cytokine interleu-
kin 10. A reduction in hepatic myofibroblasts was followed by reduced fibrosis detected 4
weeks after macrophage infusion. Serum albumin levels were elevated at this time. Up-
regulation of the liver progenitor cell mitogen tumor necrosis factor-like weak inducer of
apoptosis (TWEAK) preceded expansion of the progenitor cell compartment. Increased
expression of colony stimulating factor-1, insulin-like growth factor-1, and vascular endo-
thelial growth factor also followed BMM delivery. In contrast to the effects of differenti-
ated macrophages, liver fibrosis was not significantly altered by the application of
macrophage precursors and was exacerbated by whole BM. Conclusion: Macrophage cell
therapy improves clinically relevant parameters in experimental chronic liver injury. Para-
crine signaling to endogenous cells amplifies the effect. The benefits from this single,
defined cell type suggest clinical potential. (HEPATOLOGY 2011;53:2003-2015)
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hronic liver injury results in scar deposition,
hepatocyte loss, and ultimately cirrhosis. The
only effective treatment for endstage liver dis-
ease is liver transplantation; however, organ demand
exceeds available supply. There is, therefore, an urgent
need to develop alternative therapies for cirrhosis. BM
(bone marrow)-derived cell populations influence the
progression and recovery phases of liver fibrosis.1-3
Clinical studies of BM cell therapy for cirrhosis are
under way. However, the use of mixed cell populations
limits the understanding of mechanisms of action.4
The identification of defined single cell types with
beneficial effects will enable rational and predictable
therapy.
Macrophages have a broad repertoire of context-
dependent immune, inflammatory, trophic, and regu-
latory actions.5 We have previously shown that upon
cessation of chronic liver injury, endogenous macro-
phages mediate hepatic scar remodeling through local
matrix metalloproteinase (MMP) expression.2,6 BM
precursors differentiate into macrophages under the
control of colony stimulating factor-1 (CSF-1) via its
receptor (CSF-1R). CSF-1 also regulates macrophage
proliferation, viability, and phenotypic fate.7 Further-
more, exogenous CSF-1 stimulates macrophage infil-
tration, improving fibrosis and function in models of
renal8 and cardiac9 injury. Developing therapy using
cells from the monocyte-macrophage lineage therefore
holds promise. In chronic liver injury, hepatocyte
proliferation is impaired and liver progenitor cells
(LPCs) become activated to supply hepatocytes.10
LPCs are not of BM origin11,12; however, their acti-
vation is influenced by a number of paracrine signals
that represent potential targets for BM-derived cell
therapy.10,13
We examined the therapeutic potential of exogenous
unmanipulated BM cells, in particular those of the
monocyte-macrophage lineage, delivered during
chronic liver injury. The intraportal application of dif-
ferentiated BM-derived macrophages (BMMs)
improved liver fibrosis, regeneration, and function.
Distinct from our current understanding of endoge-
nous macrophages in postinjury scar resolution, the
application of these ex vivo cultured and expanded
cells activates a wide range of reparative pathways dur-
ing ongoing injury, with therapeutic benefit. Impor-
tantly, we observed paracrine signaling from the exoge-
nous cells to larger populations of endogenous cells,
which amplified their effects. This allowed compara-
tively modest numbers of donor BMMs to exert whole
organ changes—encouraging from a translational
perspective.
Materials and Methods
Preparation and Characterization of Donor
Cells. Femurs and tibias were removed from age-
matched, syngeneic male mice. BM cells were extracted
and a single-cell suspension prepared by passing the
cells through a 40-lm filter (BD Falcon). The
Tg(Csf1r-Gfp)Hume (MacGreen) mouse has been
characterized.14 Briefly, this transgenic model uses the
promoter region of the CSF-1R gene to direct expres-
sion of an enhanced green fluorescent protein (EGFP).
Flow cytometric analysis of MacGreen mouse BM
shows that EGFP colocalizes with CD11b, indicating
that transgene expression is confined to myeloid cells.
Approximately 50% of EGFPþ BM cells express F4/
80.14 EGFPþ BM cells expressing the Gr-1 antigen
include Ly-6Cþ monocytes and Ly-6Gþ granulocytes.
Monocytes are physiological precursors of macro-
phages. Culture with CSF-1 converts Ly-6Gþ granulo-
cytes into F4/80þ macrophages.15 Therefore, all mac-
rophage precursor cells within the BM with the
potential to respond to CSF-1 (and differentiate into
macrophages) express the EGFP reporter, allowing
their selection by fluorescence-activated cell sorting
(FACS, FACSVantage, Becton and Dickinson). BM-
derived macrophages were prepared as described16 by
BM culture for 7 days in Teflon pots using Dulbecco’s
Modified Eagle Medium (DMEM)/F12 medium con-
ditioned with CSF-1 from L929 cells. Diff-Quik stain-
ing was performed on cytospin samples. BMM marker
expression was analyzed by flow cytometry (FACSCali-
bur, Becton and Dickinson). Cells were stained using
the following preconjugated antibodies: F4/80, CD11b
(eBiosciences), Ly-6G (Biolegend), Ly-6C, CD3 and
CD19 (BD Pharmingen) with appropriate isotype con-
trols. For phenotypic comparison, naı̈ve BMMs were
classically activated (M1) by overnight stimulation
with lipopolysaccharide (Sigma, 50 ng/mL) and inter-
feron-c (Peprotech, 20 ng/mL) or alternatively acti-
vated (M2) with interleukin (IL)-4 and IL-13 (both
Peprotech, 20 ng/mL).5
Disease Models and Cell Delivery. Wildtype mice
were supplied by Harlan (UK) and housed in a sterile
animal facility with a 12-hour dark/light cycle and free
access to food and water. All animal experiments were
carried out under procedural and ethical guidelines of
the British Home Office. Advanced liver fibrosis was
induced in adult female mice over a 10- week period
by twice weekly intraperitoneal (IP) injection of 0.75
mL/kg carbon tetrachloride (CCl4) dissolved in sterile
olive oil. One day after the 12th CCl4 injection (6
weeks), mice from the same cohort were randomly
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allocated to receive either cell or control medium
injections via the hepatic portal vein (HPV). Candi-
date cells from age- and strain-matched mice were sus-
pended in 0.1 mL of DMEM. CCl4 administration
continued for a further 4 weeks. The HPV was
accessed by midline laparotomy using aseptic tech-
nique. Anesthesia was induced using 1 mg/kg medeto-
midine and 76 mg/kg ketamine intraperitoneally (IP)
and reversed with 1 mg/kg atipamezole subcutaneously
(SC). Then 22.5 lg/kg buprenorphine (SC) was given
as analgesia.
The following candidate cell types were tested: (1) 1
 106 unfractionated whole BM cells were given to
syngeneic fibrotic C57Bl/6 mice (n ¼ 6, control n ¼
6). (2) 1  106 differentiated BMMs physically dis-
rupted by sonication were given to syngeneic fibrotic
C57Bl/6 mice (n ¼ 7, control n ¼ 6) to test whether
intact, live BMMs were required for therapeutic effect.
BMMs were sonicated twice for 10 seconds at 50%
power using a Bandelin sonicator (Bandelin). (3) 1 
106 macrophage precursor cells sorted from the BM of
MacGreen mice14 on a Balb-c background were given
to fibrotic Balb-c mice (n ¼ 7, control n ¼ 6). (4) 1
 106 differentiated wildtype BMMs were given to
syngeneic fibrotic C57Bl/6 mice (n ¼ 7, control n ¼
6). As no male donor BMMs were detected 4 weeks
after BMM delivery, donor cells were also tracked by
an independent method. BMMs were derived from
the BM of constitutively GFPþ mice (TgTP6.3 tau-
GFP mice on a CBA/Ca background17) using the
same 7-day macrophage differentiation protocol as for
wildtype BMMs. The 7  106 GFPþ BMMs were
given to fibrotic wildtype CBA mice (n ¼ 7, control n
¼ 8).
BMM engraftment was transient; therefore, we
examined the early effects of BMMs on fibrotic
C57Bl/6 mice. 1  106 wildtype BMMs were given
after 6 weeks of CCl4 (n ¼ 17, control n ¼ 17).
These mice were euthanized 1, 3, or 7 days after
BMM delivery.
Additionally, 1  106 differentiated BMMs were
delivered to mice 8 weeks into a longer schedule of 12
weeks 0.4 mL/kg CCl4 (n ¼ 8, control n ¼ 8). Mice
were venesected when euthanized. Harvested livers
were split and pieces were snap-frozen in Tissue-Tek
OCT Compound (Sakura Finetek) or fixed in
formalin.
Immunohistochemistry. Collagen (Sirius red) and
immunostaining were carried out as described.1 Three-
lm sections of formalin-fixed tissue were used for
single immunostains. MMP-9, collagen 1, Dlk, and a-
smooth muscle actin (a-SMA) detection required anti-
gen retrieval with 0.01M sodium citrate pH 6.0; pan-
cytokeratin (PCK) staining additionally required pro-
teinase K solution (125 lg/mL). For Ki67, MMP-13,
and GFP detection, slides were treated with Tris-
EDTA pH 9.0. Primary antibodies were used at the
following dilutions: 1:50 for F4/80 (Abcam), 1:100
for Ly-6G (BD Pharmingen) and collagen 1 (Southern
Biotech), 1:150 for Dlk (Abcam), 1:200 for PCK
(Dako), 1:500 for Ki67 (Novo Castro), GFP and
MMP-9 (both Abcam), 1:800 for MMP-13 (Abcam),
and 1:2,000 for a-SMA (Sigma). Secondary antibody
was applied at a 1:400 dilution. Appropriate isotype
controls were used for each primary antibody. Sections
were developed using 3,30-diaminobenzidine (Dako)
then counterstained with Harris’ hematoxylin. Frozen
sections were used for dual staining with MMP-9 and
F4/80 or Ly-6G. Detection was performed with Alexa
Fluor 488, 546, and 555 (Invitrogen) followed by
mounting using Vectashield with DAPI (Vector Labo-
ratories). TUNEL staining (Promega) was performed
on formalin-fixed tissue as per the manufacturer’s
instructions; dual staining with a-SMA was detected
with streptavidin-Alexa Fluor 555 (Invitrogen). Male
cells were detected by Y chromosome fluorescent in
situ hybridization (FISH) using FITC-labeled Y-chro-
mosome paint (Star-FISH; Cambio) as described.1
Assessment of Tissue Sections. Stained slides were
blinded and a minimum of 20 serial, nonoverlapping
fields were photographed at 200 magnification. Male
donor BMMs were detected by Y chromosome FISH.
Not all male BMMs in a tissue section will exhibit the
nucleus, and therefore permit binding of the Y chro-
mosome probe. Male liver was used to establish the
proportion of nonparenchymal cells that bound the
probe (54%) and adjust subsequent counts to deter-
mine the total number of male donor cells present.
For assessment of F4/80, Ly-6G, MMP-9, and MMP-
13 staining, positive cells were counted in each field.
PCK is a sensitive and validated marker of murine
LPCs.18 LPCs were defined as PCKþ cells with typical
LPC morphology not directly abutting a lumen
(thereby excluding biliary epithelia) as described.18 For
a-SMA, collagen I and Sirius red assessment, the per-
centage staining of the total field was measured using
image analysis software (Adobe Photoshop). Measure-
ments are expressed relative to matched control recipi-
ent samples from the same timepoint.
Quantification of Protein Levels. Whole liver pro-
tein extracts were quantified by Bradford assay. Sam-
ples were used at a concentration of 10 mg/mL. Cyto-
kine concentrations were measured in duplicate using
the Bioplex Protein Array System (Bio-Rad) according
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to the manufacturer’s instructions. Data were analyzed
using Bio-Plex Manager 3.0 software (Bio-Rad). Pro-
tein levels are expressed relative to matched control
samples from the same timepoint. Commercial kits
were used to measure serum albumin (Randox Labora-
tories) and alanine aminotransferase (ALT) (Alpha
Laboratories).
Hydroxyproline Assay. Snap-frozen liver samples
(200 mg) were weighed, hydrolyzed in NaOH, and
hydroxyproline content determined as described.19 Ab-
sorbance was measured at 550 nm and hydroxyproline
content expressed as lg/g liver.
Quantification of Messenger RNA (mRNA) Levels
by Real-Time Reverse-Transcription Polymerase
Chain Reaction (PCR). RNA was extracted from
whole liver tissue using RNA extraction kits (Qiagen)
according to the manufacturer’s instructions. Comple-
mentary DNA was generated from 1 lg of RNA using
the Superscript II kit (Invitrogen). Primers for MMPs-
2, 9, 12, and 13, Fizz-1, IL-10, inducible nitric oxide
synthase (iNOS), macrophage chemoattractant protein
(MCP)-1, mannose receptor, tumor necrosis factor
(TNF)-a, and Ym-1 were designed using primer
express software (sequences supplied in the Supporting
material). Predesigned, validated primer sets for macro-
phage inflammatory protein (MIP)-1a, MIP-2, KC,
MMP-8, hepatocyte growth factor (HGF), insulin-like
growth factor-1 (IGF-1), CK-19, and TNF-like weak
inducer of apoptosis (TWEAK) were purchased from
Qiagen (UK). A predesigned, validated eukaryotic 18S
primer/probe set (Applied Biosystems) was used for in-
ternal control. Quantitative real-time PCR (qPCR)
was performed using Express SYBR Green or TaqMan
Express qPCR Supermix (Invitrogen). All reactions
were performed in triplicate. Levels are expressed rela-
tive to matched control samples from the same
timepoint.
Statistics. Data are presented as mean 6 standard
error of the mean. Two-tailed Student’s t and Mann-
Whitney U tests were used to analyze parametric and
nonparametric data, respectively using Prism (Graph-
Pad Software) unless otherwise stated.
Results
BMM Cell Therapy Improves Murine Liver Fibro-
sis. A hierarchical approach to candidate donor cell
selection from the monocyte-macrophage lineage was
taken. The effects of delivering differentiated macro-
phages (Fig. 1A-E), macrophage precursors from the
BM (Fig. 1F), and unfractionated whole BM were
tested. Macrophages were generated by 7 days of BM
culture with CSF-1 conditioned medium. Diff-Quik
staining confirmed that the injected cells were a mor-
phologically homogenous population of macrophages
(Fig. 1A). BMMs possessed the characteristic macro-
phage cell surface markers F4/80 and CD11b.20 Flow
cytometric analysis demonstrated that markers of other
leukocyte populations (monocytes, neutrophils, and T
and B cells) were not present in significant numbers
(Fig. 1B). Donor BMMs were not manipulated and
did not conform to either the traditional classically
(M1) or alternatively activated (M2) macrophage phe-
notype (Fig. 1C,D). BMMs expressed antiinflamma-
tory (IL-10), antifibrotic (MMP-13), proregenerative
(TWEAK), and chemotactic (MCP-1, MIP-1a, MIP-
2) mediators (Fig. 1E) that were subsequently found
to be elevated in BMM recipient livers (Figs. 5C, 6C,
7E,F). The 1  106 wildtype BMMs delivered to re-
cipient mice resulted in a significant reduction in fi-
brosis measured by Sirius red quantification (66% of
control, P < 0.05, Fig. 2A,B). This effect was con-
firmed by reduced hydroxyproline content (368.2 6
41.0 versus 558.8 6 94.6 lg/g liver, P ¼ 0.05, Fig.
2C) and collagen I staining (73% of control, P <
0.01, Fig. 2D,E). Experiments with GFPþ donor
BMMs in an independent strain of wildtype recipients
also demonstrated this reduction in fibrosis (Sirius red
staining 67% of control, P < 0.05, Fig. 2B, Support-
ing Fig. 1A). Furthermore, in a 12-week CCl4 injury
model, BMMs injected at 8 weeks also reduced fibrosis
to 69% of control (n ¼ 8 versus n ¼ 8 controls, P <
0.05).
In contrast to the effects of 7-day differentiated
macrophages, injecting 1  106 BM macrophage pre-
cursor cells did not significantly reduce fibrosis (P ¼
0.21, Fig. 2A,B). The 1  106 unfractionated whole
BM cells increased liver fibrosis to 161% of control (P
< 0.05, Fig. 2A,B) and 1  106 sonically disrupted
BMMs led to a trend of increased liver fibrosis (P ¼
0.08, Fig. 2B, Supporting Fig. 1B). Therefore, liver fi-
brosis was exacerbated by unfractionated BM and did
not significantly improve following the delivery of BM
macrophage precursors. Differentiated BMMs consis-
tently reduced hepatic scar and cell viability was
required; the underlying processes are examined in the
following experiments.
Transient Engraftment of BMMs in the Fibrotic
Liver. Engraftment of donor BMMs was confirmed
using two independent cell tracking techniques. GFPþ
BMMs were located by immunostaining sections of
wildtype recipient liver for GFP. Male donor BMMs
in the female recipient liver were identified by Y chro-
mosome FISH. The majority of identified donor
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BMMs were located within or closely apposed to the
hepatic scar (Fig. 3A). One day after the delivery of 1
 106 BMMs, the mean number of engrafted donor
BMMs was 6.9 per 200 magnification field by GFP
immunostaining. Y chromosome FISH revealed 6.5
donor BMMs (per 200 field) at day 1, which
decreased to 5.3 within the first week. In keeping with
the known rapid turnover of hepatic macrophages,21
donor BMMs were not detected 1 month after BMM
delivery (Fig. 3B).
Early Reduction in Myofibroblasts Following
BMM Delivery. A reduction in the number of a-
SMAþ myofibroblasts through apoptosis is a key early
event during fibrosis resolution.22 The amount of a-
SMA staining in the BMM treatment group decreased
within the first week (Fig. 4A), falling to 40% of con-
trol 7 days after macrophage therapy (P < 0.05, Fig.
4B). Apoptotic myofibroblasts were detected during
this reduction (Supporting Fig. 2). The decrease in
myofibroblasts was no longer statistically significant 1
month after intervention (P ¼ 0.29), suggesting that
the peak antifibrotic effect on the myofibroblast popu-
lation occurs soon after BMM delivery.
Up-regulation of Hepatic MMP-Expressing Cells
in BMM Recipients. A critical component of fibrosis
resolution is the degradation of extracellular matrix
mediated by the MMP family of enzymes. Prior to the
reduction in myofibroblasts 7 days after BMM deliv-
ery, there were increases in the numbers of cells pro-
ducing MMP-13 and -9 protein (P < 0.01 and <
0.05, respectively, Fig. 5A,B). These MMP-expressing
cells were predominantly located in the hepatic scar.
Within 1 day of BMM therapy, whole liver gene
expression of MMP-9 was markedly elevated (P <
0.05) alongside trends toward increases in MMP-13 (P
¼ 0.21), MMP-8 (neutrophil collagenase, P ¼ 0.17),
Fig. 1. The derivation and characterization of candidate donor cells. Macrophages were differentiated from whole BM cultured for 1 week in
CSF-1 conditioned media. (A) Diff-Quik staining of these BMMs demonstrates a uniform morphology and staining profile. Original magnification
200. (B) Flow cytometric analysis revealed that BMMs possessed the typical macrophage markers F4/80 and CD11b. Markers of other leuko-
cyte populations (monocytes, neutrophils, and T and B cells) were minimally detected. (C,D) Gene expression analysis of classical (M1) and al-
ternative (M2) macrophage activation markers revealed that BMMs have a naive phenotype in this regard. (E) qPCR analysis showed that BMMs,
prior to delivery, expressed specific antiinflammatory, antifibrotic, proregenerative, and chemotactic mediators compared to untreated fibrotic liver.
(F) BM cells expressing the CSF-1 receptor/EGFP transgene in the MacGreen mouse14 represent a population of potential macrophage precur-
sors. These cells were positively selected by FACS (denoted ‘‘EGFPþ’’).
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and MMP-12 (macrophage metalloelastase, P ¼ 0.08)
(Fig. 5C). Serial section analysis indicated that a subset
of predominantly scar associated macrophages (SAMs)
produced MMP-13 (Fig. 5D). We have previously
shown that SAMs are an important cellular source of
MMP-13 contributing to scar resolution after liver
injury.6 Dual immunostaining revealed the MMP-9
producing cells to be neither donor nor endogenous
macrophages (Fig. 5Ei) but endogenous Ly-6Gþ neu-
trophils (Fig. 5Eii). Therefore, the initial donor
Fig. 2. Cells of the monocyte-macrophage lineage have differential therapeutic effects on liver fibrosis. Advanced liver fibrosis was induced in
adult female mice by chronic administration of IP CCl4. (A) Photomicrographs show Sirius red staining for hepatic collagens 4 weeks after wild-
type BMMs, macrophage precursor cells, or unfractionated BM cells were delivered to syngeneic fibrotic mice (right-side column). Age- and
strain-matched control mice within each cohort received an equal volume of control medium (left column). Original magnification, 80. (B) Mor-
phometric analysis of Sirius red staining revealed that the delivery of differentiated BMMs (both wildtype and GFPþ) caused a reduction in the
amount of fibrosis. BM macrophage precursor cells did not significantly reduce the amount of fibrosis. Unfractionated whole BM increased liver fi-
brosis, whereas dead BMMs lead to a trend towards this. The reduced fibrosis following BMM delivery was confirmed (1-tailed analysis) by (C)
hydroxyproline assay and (D) collagen I immunostaining (original magnification 80) with (E) morphometric analysis (*P  0.05, **P < 0.01
compared with control recipients; n ¼ 6-8 per group).
Fig. 3. Donor BMMs engraft transiently in the liver. (A) Donor cells were tracked by treating wildtype fibrotic mice with GFPþ BMMs (arrowed).
Original magnification 200. In addition, male donor cells (arrowed) were detected within injured female liver using FISH for the Y chromosome.
Original magnification 320. (B) Quantification of donor cell engraftment by Y chromosome FISH revealed a reduction in number during the first
7 days after BMM delivery. No donor cells were present 4 weeks after infusion (n ¼ 3 per timepoint).
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BMMs caused an increase in the numbers of MMP-
producing leukocytes in the hepatic scar.
BMMs Initiate the Hepatic Recruitment of Circu-
lating Macrophages and Neutrophils. Within 1 day
of BMM infusion, there was a marked change in the
cellular composition of the fibrotic liver. F4/80 immu-
nostaining demonstrated a 44% increase in macro-
phages (P < 0.05, Fig. 6A,B). The absolute increase in
macrophage number in BMM-treated mice (from 53
to 76, i.e., an additional 23 per 200 field) is greater
than the number of donor BMMs (mean <7) in the
same area of tissue, indicating that the majority of
these macrophages were recruited. Ly-6G immuno-
staining revealed a 242% increase in hepatic neutro-
phils (P < 0.01, Fig. 6A,B).
Analysis of whole liver protein from this timepoint
revealed that BMM recipients had significantly higher
levels of several chemokines expressed by the donor
BMMs (Figs. 1E, 6C). The macrophage chemoattrac-
tant MCP-1 (CCL2) was increased to 160% (P <
0.001), whereas MIP-1a (CCL3) was 137% of control
(P < 0.05). The neutrophil chemoattractants KC
(CXCL1) and MIP-2 (CXCL2) were also strongly up-
regulated (242%, P < 0.001 and 842%, P < 0.01,
respectively). Whole liver protein levels of the antiin-
flammatory cytokine IL-10 were elevated to 346% in
BMM recipients (P < 0.05), whereas proinflammatory
mediators such as IL-6 and TNF-a were unchanged
(Fig. 7F). Four weeks after BMM delivery, serum ALT
levels were not significantly reduced in recipient mice
(399.2 6 120.7) compared to controls (505.7 6 91.7
u/l, P ¼ 0.5).
Therefore, BMM therapy switches the hepatic
milieu towards an antiinflammatory cytokine environ-
ment while recruiting host macrophages and neutro-
phils into this altered setting.
BMM Cell Therapy Stimulates Regeneration of
the Injured Liver. Serum albumin was increased in
BMM recipients 4 weeks after cell delivery (46.0 6 2.6
g/l versus 39.9 6 0.9 g/l, P ¼ 0.05, Fig. 7A). The ele-
vated serum albumin was confirmed in mice receiving
GFPþ BMMs (43.3 6 0.6 g/l versus 40.4 6 1.0 g/l, P
< 0.05, Fig. 7A), suggesting improved regeneration.
Hepatocyte proliferation (Ki67þ) was not significantly
increased after BMM therapy (P ¼ 0.21, Fig. 7B,C).
Expression of the hepatocyte mitogen HGF also did
not change (Fig. 7E). In keeping with human chronic
liver disease, increased numbers of LPCs were present
in CCl4-injured mice. Three days after BMM delivery,
whole tissue mRNA levels of the LPC marker CK-19
were increased by 55% over control recipients (1.55 6
0.1 versus 1.00 6 0.2, P ¼ 0.05). By day 7, there was
a periportal expansion of PCK and Dlkþ LPCs in
BMM recipients. The number of LPCs increased by
40% over control (P < 0.05, Fig. 7B,D). There was no
increase in the level of the cytokines IL-6 and TNF-a
which are associated with LPC proliferation10 (Fig. 7F).
Donor BMMs used here express high levels of the LPC
mitogen TWEAK relative to recipient liver (Fig. 1E).
Three days after BMM therapy, at a time when hepatic
macrophage numbers were increased, whole liver
TWEAK mRNA levels were significantly elevated to
216% of control (P < 0.05, Fig. 7E).
IGF-1 mRNA levels were increased 3 and 7 days after
BMM delivery (P < 0.05 and 0.001, respectively, Fig.
7E). CSF-1 protein levels increased to 165% 1 day after
BMM delivery (P < 0.01, Fig. 7F) before decreasing
over the first week. Vascular endothelial growth factor
(VEGF) protein levels increased over this period in
BMM recipients, reaching 127% of control at day 7 (P
< 0.05, Fig. 7F). In addition to the up-regulation of
these reparative factors, the increased TWEAK expression
and expanded LPC compartment are also implicated in
the improved hepatic function in BMM-treated mice.
Discussion
Cell therapy based on a defined, homogenous cell
population adds clarity to the cause-effect relationship.
Importantly for clinical translation, our data reveal that
unfractionated BM had a deleterious effect on liver fi-
brosis. Interestingly, exogenous macrophage precursors
Fig. 4. BMM delivery causes a reduction in hepatic myofibroblasts.
(A) Photomicrographs demonstrate the reduction in a-SMAþ myofibro-
blasts 7 days after BMM delivery. Original magnification 80. (B)
Quantification of a-SMA immunostaining revealed that myofibroblast
numbers declined within 7 days of BMM treatment; this effect did not
persist 1 month after infusion (*P < 0.05 compared with control
recipients per timepoint; n ¼ 5-8 per group).
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did not significantly improve liver fibrosis. Of note,
this population contains Gr-1hi (Ly-6Chi) monocytes15
that have profibrogenic actions during liver injury.23
Following culture in CSF-1 conditioned medium,
CSF-1Rþ macrophage precursors within BM differen-
tiate into macrophages.15 The BMMs used here are a
relatively homogenous population of cells without sig-
nificant contamination from other cell types such as
monocytes, granulocytes, and stem cells. The differenti-
ated macrophages generated by this process are antifi-
brotic and proregenerative in this model. Unmanipu-
lated BMMs cultured in these nonadherent conditions
possess neither the typical classically (M1) nor alterna-
tively activated (M2) profiles. Donor BMM engraft-
ment was transient; however, their effects persisted and
were amplified by paracrine signaling to host cell
Fig. 5. BMM delivery causes the hepatic up-regulation of MMPs-13 and -9. (A) Immunohistochemical analysis of livers 1 day after BMM deliv-
ery revealed infiltration of MMP-13 and MMP-9þ cells (arrowed). Original magnification 320 and 200, respectively. (B) The numbers of
MMP-13 and -9-expressing cells were greater than in control recipients. (C) Whole liver gene expression of MMP-9 was significantly elevated in
BMM recipients at this timepoint. Gene expression levels of MMPs-8, -12, and -13 were not significantly increased. By day 3, these levels had
decreased (*P < 0.05, **P < 0.01 compared with control recipients per timepoint; n ¼ 5-6 per group). (D) Immunostaining of serial liver sec-
tions indicates that a subset of scar associated F4/80þ macrophages produced MMP-13 (arrowed). Original magnifications 80 and 320. (E
i) Dual staining for MMP-9 (red) and F4/80 (green) demonstrates that hepatic macrophages (arrowheads) did not express MMP-9 (arrows) in
BMM recipients. Original magnification 1000. (E ii) Colocalization (arrows) of the neutrophil marker Ly-6G (red) with MMP-9 staining (green)
indicates that scar associated hepatic neutrophils were expressing MMP-9 in BMM recipients. Original magnification 200.
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populations. The net effect was a reduction in fibrosis
and improved regeneration of the injured liver.
BMM therapy caused the recruitment of MMP pro-
ducing host cells into the hepatic scar. MCP-1 and
MIP-1a are members of the CC chemokine subfamily
that bind to the CCR2 and CCR1/5 receptors of
monocytes, respectively. These interactions contribute
to the navigation of monocytes into target tissues dur-
ing their maturation into macrophages.5 The delivery
of MCP-1 and MIP-1a-expressing BMMs to injured
mice caused up-regulation of hepatic MCP-1 and
MIP-1a and the recruitment of endogenous macro-
phages. These macrophages produced MMP-13, whose
actions include the degradation of fibrillar collagens
and gelatin as well activation of other MMPs (such as
MMP-9).6 Donor BMMs also express MIP-2 and KC,
which are examples of CXC chemokines that recruit
neutrophils through the surface receptor CXCR2.5
One day after BMM delivery, hepatic expression of
these neutrophil chemoattractants was markedly up-
regulated, with elevated hepatic neutrophil numbers.
This is in keeping with the role of macrophage-medi-
ated neutrophil recruitment in fibrosis resolution fol-
lowing cessation of cholestatic injury.24 In our model,
recruited neutrophils produce MMP-9. MMP-9 over-
expression reduces myofibroblast number and inhibits
Fig. 5. (Continued)
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fibrogenesis during experimental liver injury.25 The si-
multaneous trend of increased MMP-12 (macrophage
metalloelastase) and MMP-8 (neutrophil collagenase)
expression following BMM therapy reinforces the fibro-
lytic role of recruited leukocytes. The markedly ele-
vated hepatic IL-10 levels in BMM recipients may
modify the behavior of resident and incoming leuko-
cytes and the degree of injury.26 Simultaneous up-regu-
lation of IL-10 and MMPs following BMM therapy
may reduce myofibroblast activation26 and promote ap-
optosis.27 The chemokine-mediated recruitment of
host effector cells to the injured liver, importantly at a
time when the prevailing hepatic environment is antiin-
flammatory, represents a novel and realistic mechanism
for the therapeutic actions of comparatively few donor
cells in the context of the whole organ.
The improved liver function following BMM ther-
apy is multifactorial. There is a less fibrotic cellular
milieu, a proregenerative stimulus to LPCs, and ele-
vated levels of cytokines such as CSF-1, VEGF, and
IGF-1 that are involved in reparative processes dur-
ing tissue injury.9,28,29 Hepatocyte proliferation was
not significantly increased following BMM therapy.
There was significant activation of the LPC compart-
ment, compatible with the recent observation that
BM infusion transiently stimulated LPCs and
improved serum albumin in a series of cirrhotic
patients.30 We have previously noted the close spatial
relationship between LPCs and endogenous macro-
phages in vivo.12 The cytokine TWEAK is a member
of the TNF superfamily and is currently the only
known mitogen that is selective for LPCs but not
Fig. 6. Host leukocytes are recruited to the liver following BMM delivery. (A) Immunohistochemical analysis of livers 1 day after BMM delivery
revealed that macrophages and neutrophils were recruited to the injured liver. Original magnification 200. (B) The degree of cell influx was
greater than in control tissue. (C) Whole liver protein expression of macrophage and neutrophil chemokines (MCP-1, MIP-1a, MIP-2, and KC)
was significantly up-regulated 1 day after BMM delivery. By day 3 these levels returned toward baseline (*P < 0.05, **P < 0.01 compared
with control recipients per timepoint; n ¼ 5-6 per group).
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mature hepatocytes.13 TWEAK acts through its cog-
nate receptor Fn14 to stimulate LPC proliferation.
Interestingly, endogenous hepatic macrophages have
recently been identified as a cellular source of
TWEAK during chronic liver injury.31 Donor
BMMs used in our studies expressed high levels of
TWEAK and recruited additional host macrophages
to the injured liver, supporting the paradigm of do-
nor cell-derived paracrine signals having downstream
actions on host cell populations. In addition, we
Fig. 7. BMM therapy activates regenerative pathways. (A) Serum albumin was increased 4 weeks after the delivery of wildtype or GFPþ BMMs
to fibrotic mice. (B) Photomicrographs show Ki67, PCK, and Dlk staining of liver tissue 7 days after BMM therapy. Original magnification 200.
(C) The number of Ki67þ hepatocytes did not increase significantly after BMM therapy. (D) Increased numbers of pancytokeratin-positive liver
progenitor cells were detected 7 days after BMM infusion. This expansion was not maintained at 4 weeks. (E) Gene expression of HGF was not
significantly elevated in BMM recipients. The liver progenitor cell mitogen TWEAK was up-regulated 3 days after BMM delivery. IGF-1 mRNA was
increased 3 and 7 days after BMM treatment. (F) Whole liver protein levels of IL-10 and CSF-1 were elevated 1 day after BMM delivery, whereas
IL-6 and TNF-a were unchanged. VEGF protein levels increased after BMM therapy, reaching significance at day 7 (*P  0.05, **P < 0.01 com-
pared with control recipients per timepoint; n ¼ 5-8 per group).
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have recently found that hepatic scar degradation
promotes LPC activation,32 suggesting that LPC pro-
liferation is also indirectly enhanced by the macro-
phage-mediated hepatic scar reduction.
In conclusion, we have demonstrated the benefit
of BMM therapy upon structural and functional pa-
rameters of chronic liver injury. BMMs clearly have
multiple actions, some direct and others mediated
indirectly through recruitment of host effector cells
with antiinflammatory, antifibrotic, and proregenera-
tive results. A number of the mediators reported
here have previously been shown to determine the
course of experimental liver injury. When overex-
pressed in isolation, MMP-9,25 IGF-1,29 and IL-1026
have each been shown to reduce myofibroblast num-
bers and fibrosis in injured liver. CSF-1 also reduces
organ fibrosis while improving function.8,9 MMP-13
knockout impairs fibrosis resolution6 and MMPs-8
and -12 mediate hepatic scar degradation. Overex-
pression of TWEAK and IL-10 improve LPC prolif-
eration13,31 and hepatic regeneration,26 respectively.
The simultaneous up-regulation of these factors dem-
onstrates the multifaceted effects of cell therapy. This
contrasts with studies of single molecules or genes
where the effects of the single pathway can be
shown. Future work will examine the cellular events
underpinning leukocyte recruitment and also activa-
tion of progenitor cells within the injured liver fol-
lowing BMM therapy. With regard to clinical trans-
lation, the use of a differentiated, readily available,
single cell type increases the predictability of effect.
The data reported here will inform the rational
design of clinical studies to determine the efficacy of
autologous cell therapy in chronic liver disease.
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